NZ563447A

NZ563447A - Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(S)-carbonitrile formulation

Info

Publication number: NZ563447A
Application number: NZ563447A
Authority: NZ
Inventors: James Kowalski; Jay Parthiban Lakshman; Abu T M Serajuddin; Yatindra Joshi
Original assignee: Novartis Ag
Priority date: 2005-06-10
Filing date: 2006-06-08
Publication date: 2012-02-24
Also published as: CA2610422A1; DE602006009656D1; AR054383A1; EP1898904B1; IL187420A0; ES2385129T3; US20110086096A1; ES2334261T3; NO20080177L; JP2013177428A; PE20150728A1; PL1898904T3; PE20070691A1; EP2191824A1; RU2007148241A; BRPI0613499A8; IL187420A; MY152185A; US20100021539A1; PL2191824T3

Abstract

Disclosed is a pharmaceutical tablet formulation comprising per unit dosage form the following ingredients: (a) a compound as an active ingredient, wherein the compound is (s)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyanopyrrolidine (vildagliptin) or the corresponding amount of any of its salts; and (b) hydroxypropyl methylcellulose and one or more fillers.

Description

<div class="application article clearfix" id="description"> WO 2006/135723 1 PCT/US2006/022416 Modified Release 1-[(3-Hydroxy-adamant-l-ylamino)-acetyl]-pyrrolidine-2(S)-carbonitrile Formulation 5 Background of the Invention The present invention relates to a sustained release preparation containing a dipeptidyl peptidase IV inhibitor (DPP-IV) useful for preventing or treating diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, arthritis, osteoporosis, 10 and other diseases. DPP-IV is a useful drug for treating diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, arthritis, osteoporosis, and other diseases because it inhibits inactivation of glucagons-like peptide-I (GLP-I) in blood plasma 15 and increases its incretion action (WO 02/062,764, WO 01/55105, WO 02/02560). However, as described in detail below, there were some cases in which strong inhibition of DPP-IV activity in a living body was not always preferable. 2 0 For example, it has been reported that the DPP-IV inhibitor enhances vasodialation action by substance 0 and that the DPP-IV activity was elevated when treating chronic rhinosinusitis because there was an inverse relationship between DPP-IV activity of nasal mucosa of a patient with chronic 25 rhinosinusitis and density of inflammatory cells on the nasal mucosa (for example, FASEB J., 2002, 16:1132-1134). Accordingly, it is considered undesirable to strongly inhibit DPP-IV activity in a patient with diabetes complicating chronic inflammation because it results in aggravation of inflammation. 30 It has been reported that selective DPP-IV activity is important for glucose homeostasis since GLP-I (9-36) amide, a metabolite from GLP-I with DPP-IV, reduces blood glucose level (Am. J. Physiol. Endocrinol. Me tab., 2002, 282:E873-E87 9) . WO 2006/135723 PCT/US2006/022416 Further it has been reported that in treatment of a patient with type C Hepatitis using interferon-a, severity of depression and anxiety correlated with decrease of serum DPP-IV activity (for example, Mol. Psychiatry, 2001, 6:475-480). 5 In view of the current circumstances that there are some cases in which strong inhibition of in vivo DPP-IV activity is not always preferable for the living body, the present inventors considered it necessary to develop a preparation that could appropriately inhibit DPP-IV activity and also afford excellent 10 convenience or compliance. The inventors herein disclose a modified/sustained release 1-[(3-Hydroxy-adamant-l-ylamino)-acetyl]-pyrrolidine-2(S)— carbonitrile (also known as LAF237 or vildagliptin (INN)) formulation for these purposes. The development of a 15 modified/sustained release (MR) formulation comprising vildagliptin is necessary to improve the treatment quality of the treated patients. vildagliptin is an orally active, dipeptidylpepidase IV inhibitor indicated for improvement of glycemic control in type II diabetes. 20 LAF237 is specifically disclosed in Example 1 of WO 00/34241. LAF237 can be formulated as described in WO 00/34241, or in the International Patent Application No. EP2005/000400 (application number). Since vildagliptin is sensitive to moisture, one of the main 25 emphases during the Market Formulation (MF) development was product stability. Hydrolysis is the main degradation pathway for vildagliptin. The stability of vildagliptin is known to be affected by initial moisture content of the tablet, excipients with high intrinsic moisture and the amount of excipients 30 present in the tablet (% drug load) . The current validated vildagliptin formulation is a DC (direct compression) tablet with a 25% drug load. Considering the water-sensitivity of vildagliptin, Clinical service form (CSF) and Market Formulation (MF) development was Received at IPONZ 15 April 2011 -3- planned to focus on techniques that would not require the use of water, such as direct compression. vildagliptin is classified as Category II, therefore, no special handling practices are required. 5 The vildagliptin drug substance (DS) is sensitive to moisture. Very tight packaging is necessary. Current retest date is 30 months with storage at 25°C. It is well known that patient adherence to a drug regimen indirectly correlates with frequency of dosing i.e. greater 10 adherence is seen with a once daily (OD) dosing regimen compared to a twice daily (BID) dosing regimen. The majority of data currently available for vildagliptin is derived from studies based on the immediate release (IR) formulation of vildagliptin given BID. 15 Replacing the 50mg IR BID dose with a OD modified release dose will provide the dual benefit of dosing convenience to the patient and a inovative OD product for treating patients. The present invention provides a pharmaceutical tablet formulation, capable of being compressed, preferably directly 20 compressed, into a tablet having adequate hardness/friability, an acceptable disintegration time, low sensitivity to moisture, improved stability, an acceptable dissolution pattern and improved pharmacokinetic profile in treated patients. The pharmaceutical tablet formulation, can also be used in e.g. a 25 capsule, tablet, compressed table, direct compressed tablets, granule. Summary of the Invention In one aspect, the invention comprises a pharmaceutical tablet formulation comprising per unit dosage form the following 30 ingredients: (followed by page 3a) RECIEVED IPONZ 10 NOVEMBER 2011 -3a- (a) a compound as an active ingredient, wherein the compound is (s)-1-[ (3-hydroxy-l-adamantyl)amino]acetyl-2-cyano-pyrrolidine (vildagliptin) or the corresponding amount of any of 5 its salts; and (b) hydroxypropyl methylcellulose K100M; and one or more fillers and optionally a lubricant. In another aspect, the invention comprises a pharmaceutical tablet formulation, comprising per 600 mg tablet the following 10 ingredients: (a) vildagliptin in an amount of 150 mg, or the corresponding amount of any salt thereof; (b) hydroxypropyl methylcellulose K100M in an amount of about 24 0 mg; 15 (c) a microcrystalline cellulose in an amount of 180 mg; (d) a lactose in an amount of about 24 mg; and (e) a magnesium stearate in an amount of 6 mg. In even another aspect, the invention comprises a pharmaceutical tablet formulation, comprising per 400 mg tablet the 20 following ingredients: (a) vildagliptin in an amount of 100 mg, or the corresponding amount of any salt thereof; (b) hydroxypropyl methylcellulose K100M in an amount of about 160 mg; 25 (c) a microcrystalline cellulose in an amount of 120 mg; (d) a lactose in an amount of about 16 mg; and (e) a magnesium stearate in an amount of 4 mg. (followed by page 3b) RECIEVED IPONZ 10 NOVEMBER 2011 -3b- In yet another aspect, the invention comprises a method of producing the pharmaceutical tablet formulation according to a preceding aspect, where the method comprises combining the ingredients in the amounts recited in any one of these claims. 5 In still another aspect, the invention comprises a pharmaceutical multilayer tablet wherein the pharmaceutical tablet formulation according to a preceding aspect represents one of the layers of the tablet. In still another aspect, the invention comprises a process for 10 preparing a tablet, in unit dosage form, the process comprising the steps of: (a) blending a pharmaceutical tablet formulation according to a preceding aspect; (b) compressing the formulation prepared during step 15 (a) to form the compressed tablet in unit dose form. In yet one other aspect, the invention comprises the use of ingredients in amounts recited in a preceding aspect, in the manufacture of a pharmaceutical tablet formulation for treating or ameliorating a condition, wherein said condition is 20 selected from: non-insulin-dependent diabetes mellitus, arthritis, obesity, allograft transplantation, calcitonin-osteoporosis, heart failure, impaired glucose metabolism, impaired glucose tolerance, neurodegenerative disorders, cognitive disorders, cardiovascular diseases, renal diseases, 25 hyperlipidemia, symptoms associated with hyperlipidemia, abnormal VLDL, LDL or Lp(a) levels, conditions requiring a sedative or anxiolytic effect, or in the manufacture of a tablet formulation for attenuating postsurgical catabolic changes, or hormonal responses to stress, or 30 for reducing mortality or morbidity after myocardial infarction. As well as the formulation, tablet, method, process and use described above, the present specification includes a broad description of this subject matter. While the present invention (followed by page 3c) RECIEVED IPONZ 10 NOVEMBER 2011 -3c- is directed to the formulation, tablet, method, process and use as defined in the claims, the invention is further illustrated with reference to this broad description. For the purposes of this specification, use of the word "invention" will be 5 understood to encompass both this broad description and the description of the invention as claimed. The subject invention provides a pharmaceutical tablet formulation comprising per unit dosage form e.g. per tablet the following ingredients: 10 a compound as an active ingredient, wherein the compound has a formula: (followed by page 4) WO 2006/135723 PCT/US2006/022416 (b) (c) (d) R(ch2)„ wherein R is substituted adaraantyl and n is an integer from 0 to 3; or a pharmaceutically acceptable salt thereof; a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution; a microcrystalline cellulose; and a magnesium stearate 10 The subject invention also provides a pharmaceutical tablet formulation, comprising per 400 mg tablet the following 15 ingredients: (a) (b) 20 25 vildagliptin or a pharmaceutically acceptable salt thereof in an amount of about 100 mg; a hydroxypropyl methylcellulose in an amount of about 160 mg, wherein the hydroxypropyl methylcellulose has an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution; (c) a microcrystalline cellulose in an amount of 120 mg; (d) a lactose in an amount of about 16 mg; and (e) a magnesium stearate in an amount of 4 mg. The subject invention also provides a pharmaceutical tablet formulation comprising per unit dosage form e.g. per tablet the following ingredients: (a) a compound as an active ingredient, wherein the compound has a formula: WO 2006/135723 PCT/US2006/022416 -5- R(CH2)n wherein R is substituted adamantyl and n is an integer from 0 to 3; or a pharmaceutically acceptable salt thereof; and (b) a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution. Brief Description of the Figures 10 Figure 1. Process Flow. This figure shows the selected manufacturing process. Figure 2. Dissolution Profile for Fast and Slow Release. Figure 3. vildagliptin MR lOOmg tablet compression profile for CSF formulation containing 40% HPMC. 15 Figure 4. vildagliptin MR 100 mg tablet friability for CSF Formulation containing 40% HPMC. Figure 5. Effect of roller compaction and dwell time, 30% HPMC, lOOmg tablet. 30% HPMC was evaluated to improve the compression profile. The effect of the tablet dwell time was simultaneously 20 evaluated at speeds from 40 to 80rpm. Figure 6. Effect of roller compaction on lOOmg tablet hardness. A Fitzpatrick (Chilsonator, model IR220) was evaluated with the interim powder blend without the addition of magnesium stearate, at increasing compaction forces. 25 Figure 7. Effect of roller compaction on 150mg tablet hardness. A Fitzpatrick (Chilsonator, model IR220) was evaluated with the interim powder blend without the addition of magnesium stearate, at increasing compaction forces. WO 2006/135723 PCT/US2006/022416 Figure 8. Effect of roller compaction on the lOOmg MR dissolution profile. The effect of roller compaction on the dissolution profile was studied with 40% HPMC K100M and compared to the dissolution profile of the clinical batch. 5 Figure 9. Effect of roller compaction on the 150mg MR dissolution profile. The effect of roller compaction on the dissolution profile was studied with 40% HPMC K100M and compared to the dissolution profile of the clinical batch. Figure 10. Effect of roller compaction on vildagliptin lOOmg 10 hardness using a Bepex roller compactor. The effect of increasing compaction forces was studied. Figure 11. Effect of roller compaction on vildagliptin 150 mg tablets using Bepex roller compactor. The effect of increasing compaction forces was studied. 15 Figure 12. Effect of roller compaction on lOOmg tablet. The effect of Fitzpatrick (Chilsonator, model IR220) roller compactor at compaction forces from 500 to 10,000 lb/in on a powder blend containing 40% HPMC. Figure 13. Effect of roller compaction on 150mg tablets. The 20 effect of Fitzpatrick (Chilsonator, model IR220) roller compactor at compaction forces from 500 to 10,000 lb/in on a powder blend containing 40% HPMC. Figure 14. Effect of roller compaction on lOOmg tablet friability. Roller compaction forces greater than 5,000 lb/in 25 (or 43.75 KN) produced tablets with a compression profile worse than the CSF without roller compaction or pre-compression. Figure 15. Effect of roller compaction on HPMC concentration and dwell time with lOOmg tablet. Figure 16. Effect of roller compaction on HPMC concentration 30 and dwell time with 150mg tablet. Figure 17. Dissolution profile for lOOmg tablet. Figure 18. Dissolution profile for 150mg tablet. WO 2006/135723 PCT/US2006/022416 -7- Figure 19. Effect of roller compaction on sieve analysis. Figure 20. Effect of roller compaction on sieve analysis. Detailed Description of the Invention 5 Terms "DPP-IV inhibitor" means a compound that inhibits enzymatic activity of DPP-IV [Classification by IUBMB; EC3.4.14.5]. The compound may be either peptidyl or non-peptidyl. As long as the DPP-IV inhibitor retains its inhibitory activity, the form may 10 be different before and after administration into the living body. Namely, the DPP-IV inhibitor may be "active metabolites" which have DPP-IV inhibitory activity after undergoing structural changes through metabolism in the living body. Further, the DPP-IV inhibitor may be a "prodrug" that is changed 15 into an activated form by reactions with enzymes, stomach acids, etc. under in vivo physiological conditions. In addition, the DPP-IV inhibitory activity can be confirmed by utilizing, for example, the method by Raymond et al. (Diabetics, 1998, 47:1253-1258) . 2 0 Specific examples of the DPP-IV inhibitor include (1) A compound of the formula: (wherein ring A is a 5- to 10-membered aromatic ring which may be substituted; R1 and R2 are each a hydrocarbon group which may 25 be the same or different and may be substituted, or a heterocyclic group which may be substituted; X is a bond, -0-, -S-, -SO-, -S02-, or -NR3-(R3 is a hydrogen atom or a hydrocarbon WO 2006/135723 PCT/US2006/022416 -8- group which may be substituted); and L is a divalent hydrocarbon group) described in WO 02/062764. The compound represented by formula (I) may be an anhydrous or hydrous substance, as well as a prodrug. 5 Suitable examples of the compound represented by formula (I) include the following compounds. Compound I-a A compound wherein the ring A is a benzene ring which may have 1 or 2 substitutions selected from: 10 1) a cyano group; 2) a Ci-io alkyl group (preferably, ethyl) or a C2-io alkenyl group (preferably, ethenyl) which may be substituted with a carbamoyl group or a carboxyl group, respectively; 3) a hydroxyl group whch may be substituted (preferably, a 1-10 15 C alkoxy group (preferably, methoxy, isopropoxy) which may have 1 to 3 substituents selected from a carbomoyl group, a carboxyl group and a 2-5 C alkoxycarbonyl group (preferably, methoxycarbonyl); a hydroxyl group; a 7-13 C aralkyloxy group (preferably, benzyloxy)) (more preferably carbamoylmethoxy); 20 4) an acyl group (preferably, a Ci_6 alkyl-carbonyl (preferably acetyl), carbamoyl, mono- or di-(Ci_6 alkyl which may have 1 to 3 subsitutents selected from a halogen atom and a Ci-$ alkoxycarbonyl) -carbamoyl (preferably, methycarbamoyl, ethycarbamoyl, 25 propylcarbamoyl, dimethylcarbamoyl, trifluoroethylcarbamoyl, ethoxycarbonylmethyl carbamoyl, etc.) C3_10 cycloalkyl-carbamoyl (preferably, cyclopropylcarbamoyl) , C7_i3 aralkyl-carbamoyl (preferably, benzylcarbamoyl), a nitrogen-containing heterocycle-carbonyl which may be substituted with hydroxyl 30 (preferably, pyrrolidinylcarbonyl, piperidinocarbonyl) , Cx_6 alkylsulfonyl (preferably, methylsulfonyl), a Cx-6 alkylsulfinyl (preferably, methylsulfinyl), carboxyl, Ci-e alkoxy-carbonyl (preferably, methoxycarbonyl), and thiocarbamoyl); 5) an amino group which may be substituted (preferably, WO 2006/135723 PCT/US2006/022416 carbamoylamnino) ; 6) a thiol group (preferably, a 1-10 C alkylthio group which may be substituted with a carbamoyl group (preferably methylthio); 5 7) a heterocyclic group which may be substituted (an aromatic theterocyclic group (preferably, furyl, thienyl, oxazolyl, oxadiazolyl, thiazolyl, tetrasolyl, pyridyl, pyrrolyl, triazolyl) or a non-aromatic heterocyclic group (preferably, dioxoisoindole, 5-oxooxadiazole-3-yl, 5-oxothiaxialole 3-yl), 10 respectively, which may have 1 or 2 substituents preferably selected from a Ci_6 alkyl group which may be substituted with 1 to 3 halogen atoms (preferably, methyl, trifluoromethyl), a carboxyl group, a 2-8 calkoxy carbonyl (preferably, ethoxycarbonyl), a cyano group, a carboamoyl group, anamino 15 group, a mono- or di-C2-io alkanoylamnio group (e.g. acetylamnio isopentanoylamnio) , Cj-io alkoxy-carbonylamnio group (e.g. methoxycarbonylamnio) , a carbamoylamino group, a mono- or di-Ci_ io alkyl-carbamoylamnio group (e.g., methylcarbmoylamino, dimethylcaramoylamino) , a C6-14 aryl-carbonylaminogroup (e.g., 20 benzoylamnio) , a C3_i0 cycloalkyl-carbonylamnio group, a C7_13 aralkyloxy-carbonylamnio, dimethylsulfonylamnio), a mono- or di-Cx_10 alkyl sulfonyl amino group (e.g., methyl sulfonyl amino, diemthyl sulfonylamino) , a C6_i4 arylsulfonylamnio group and a Gi_ 6 alkoxy-carbanoylamnino group (e.g., methoxycarbamoylamnio); 25 8) a benzene ring, which may have 1 or 2 substituents sleeted from amidino groups; R1 is a 4-10 C alkyl group (preferably, isobutyl, neopentyl) or a 4-10 cycloalkylalkyl group (preferably, cyclopropylmethyl) ; R2 is a 6-14 C aryl group 30 (preferably phenyl) which may have 1 or 2 substituents selected from a halogen atom (preferably, fluorine, chlorine) and C;l_6 alkyl (preferably methyl) ; X is a bond; and L is Ci_i0alkylene (preferably, -CH2~) . Compound I-b WO 2006/135723 PCT/US2006/022416 -10- A compound wherein the ring A is a benzene ring which may have 1 or 2 substituents selected from: 1) a Ci-io alkyl group (preferably, ethyl) or a C2_10 alkenyl group (preferably, ehthenyl) which may be substituted with a 2-8 5 C alkoxycarbonyl group (preferably, ethoxycarbonyl) or a carbamoyl group, respectively; 2) a hydroxyl group which may be substituted (preferably, a 1-10 C alkoxy group (preferably, methoxy) which may be substituted with a carbamoyl group; more preferably, carbamoylmethoxy); 10 3) an acyl group (preferably, carbamoyl, thiocarbamoyl, carboxyl); 4) a heterocyclic group which may be substituted (an aromatic heterocyclic group (preferably, furyl, rhienyl, oxazoyl, oxadiazolyl, thiazolyl, tetrasolyl, pyridyl, pyrrolyl, triazoyl) 15 or a non-aromatic heterocyclic group (preferably, 5-oxooxadiazole-3-yl), which may have 1 or 2 substituents preferably selected from a Cx_6 alkyl group (preferably, methyl), a carboxyl group, a 2-8 C alkoxycarbonyl group (preferably, ethoxycarbonyl), a cyano group, a carbamoyl group, an amnio 20 group, a mono- or di-C2-io alkanoylamnino group (e.g., acetylamnio, isopentanoylamino), Ci_10 alkoxy-carbonylamnio group (e.g. methoxycarbonylamnio), a carbamoylamnio group, a mono- or di-Ci_io alkyl-carbamoylamnio group (e.g., methylcarbamoylamnio, dimethylcarbamoylamino group), a Ce-U aryl-carbonylamnio group 25 (e.g., benzoylamino) , a C3-10 cycloalkyl-carbonylamino group (e.g., methylsulfonylamino, dimethylsulfonylamino), C 6_14 arylsulfonylamnio group and a C;i_5 alkoxy-carbamoylamino group (e.g., mehtoxycarbamoylamino) ) ; R1 is a 4-10 C alkyl group (preferably, isobutyl, neopentyl) or a 4-10 C cycloalkylalkyl ' 30 group (preferably, cyclopropylmethyl) ; R2 is a 1-10 C alkyl group (preferably, butyl) which amy be substituted with 1 to 3 halogen atoms; X is -0-; and L is Cx_10 alkylene (preferably, -CH3-). Among the compounds represented by formula (I), preferably are, 35 especially, 1—[2—[(5-cyanopyridin-2-yl)amino]ethylamino]acetyl- WO 2006/135723 PCT/US2006/022416 -11- 2-cyano(S)-pyrrolidone; l-[(3-hydroxy-adamant-l-ylamino)- acetyl]-pyrrolidine-2(S)-carbonitrile; 2-[3-(aminomethyl)-4- butoxy-2-isobuthyl-l-oxo-1,2-dihydro-6-isoquinolyl[-1,3- thiazole-4-carbonitrile; 2-[3-(aminomethyl)-4-butoxy-2- 5 isobuthyl-l-oxo-1,2-dihydro-6-isoquinolyl]-1,3-thiazole-4- carboxylic acid; 2-[3-(aminomethyl)-4-butoxy-2-isobuthyl-l~oxo-1,2-dihydro-6-isoquinolyl]-1,3-thiazole-4-carboxamide; ethyl 2-[3-(aminomethyl)-4-butoxy-2-isobuthyl-l-oxo-l,2-dihydro-6-isoquinolyl]-1,3-thiazole-4-carboxylate; (E) 3-[3-(aminomethyl)-10 4-butoxy-2-isobuthyl-l-oxo-l,2-dihydro-6-isoquinolyl]-2- propenamide; (E)-3-[3-(aminomethyl)-2-isobuthyl-4-phenyl-l-oxo-l,2-dihydro-6-isoquinolyl]-2-propenamide; 3-(aminomethyl)-2- isobuthyl-l-oxo-4-phenyl-l,2-dihydro-6-isoquinolinecarboxamide; 2-{[3-(aminomethyl)-2-isobuthyl-4-phenyl-l-oxo-l,2-dihydro-6-15 isoquinolyl]oxy}acctamide. (2) A compound represented by a formula (wherein f is 1 or 2; g is 0, 1 or 2; X is -CH2-, -0-, -S-, -SO-, —S02— or -NR3- (R3 is a hydrogen atom or a Cx-6 alkyl group) ; R 20 is a hydrogen atom, a cyano group, -CHO, -B(OH)2, P(O) (O-R3) , CC-R4, or CH=N-R5(R4 is a hydrogen atom, a fluorine atom, Ci_6 alkyl group, cyano group, nitro group, -OR3, -C02R3, or -COR3 (R3 indicates the same meaning as aforementioned) ; R5 is a phenyl group, hydroxyl group, -OR3, -OCOR3, or benzyloxy group (R3 25 indicates the same meaning as aforementioned); and A indicates an amino acid residue which may be substituted) described in WO 95/15309 etc. In the formula, the Ci_6 alkyl group indicated by the R3 includes, for example, methyl, ethyl, propyl, isopropyl, butyl, (ID R WO 2006/135723 PCT/US2006/022416 -12- isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethyl, 2,2-dimentylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl and the like. The amino acid residue in "amino acid residue which may be 5 substituted" indicated by A includes a group in which OH of a carboxyl group constituting a- or (3-amino acids has been removed from these amino acids. Herein, a-amino acids include, for example, alanine, arginine, asparagine, aspartic acid, glutamine, glutamic acid, glycine, 10 histidine, isoleucine, leucine, lycine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, citrulline, ornithine, homocystein and the like. p-Amino acids include, for example, (3-alanine, p-aminocyclopropanoic acid, p-aminocyclobutanoic acid, (3- 15 aminocyclopentanoic acid, (3-aminocyclohexanoic acid, (3-aminocycloheptanoic acid, (3-aminocyclooctanoic acid. The (3-amino acids may have unsaturated bonds in a carbon chain constituting the amino acids. The a- and (3-amino acids as described above may be in any of D-, 20 L-, and DL-forms, preferably in the natural type of L form. The said amino acid residue may have 1 or 2 substituents on an amino group constituting the amino acid or on the side chain of the amino acid. The said "substituted on the amino group" includes preferably a 25 hydrocarbon group which may be substituted and a piperidinyl group which may be substituted. A hydrocarbon group in the "hydrocarbon group which may be substituted" includes, for example, a Ci-e alkyl group, a C3.12 cycloalkyl group, a C2-6 alkenyl group, a C3_i2 cycloalkenyl 30 group, a C2-6 alkenyl group, a C4-12 cycloalkadienyl group, a C6-14 aryl group (preferably, phenyl group) , a C7_i5 aralkyl group (preferably, benzyl group, phenethyl group), an adamantly group, WO 2006/135723 PCT/US2006/022416 -13- a bicycle [2,2,1]heptyl group, a bicyclo[3,1,1]heptyl group and the like. The hydrocarbon group may have 1 to 3 substituents at substitutable positions, and such substitutions include, for 5 example, a halogen atom (preferably, fluorine, chlorine); a cyano group; a hydroxyl group which may be substituted with an acyl group; a hydroxymethyl group; a Cj-6 alkoxy group which may be substituted with 1 to 3 halogen atoms (preferably fluorine); and an amino group which may be mono- or di-substituted with a 10 0(5-14 aryl group which may be substituted or a heterocyclic group which may be substituted. Herein, an acyl group on the "hydroxyl group which may be substituted with an acyl group" includes, for example, the one exemplified as a substitutent on ring A in the said compound I-15 a. A CV14 aryl group in the "C6_i4 , aryl group which may be substituted" includes, for example, a phenyl group or a naphthyl group. A heterocyclic group in the "heterocyclic group which may be 20 substituted" includes, for example, a pyridiyl group, a pyrimidyl group, a pyrazyl group, a quinolyl group, an isoquinolyl group, a quinoxalyl group and the like. The Cs_i4 aryl group and heterocyclic group may have 1 to 3 substituents at substitutable positions and such substituents 25 include, for example, a halogen atom (preferably, fluorine, chlorine, bromine) ; a cyano group; a nitro gr-oup; a Ci_6 alkyl group; a C^6 alkoxy group which may be substituted with 1 to 3 halogen atoms (preferably fluorine); a carboxyl group; a carbamoyl group; a Ci_6 alkylsulfonyl group (preferably, 30 methanesulfonyl group); an aminosulfonyl group which may be mono- or di-substituted with C^g alkyl group (preferably diemethylaminosulfonyl group). Especially preferable for a substiutent in the said "hydrocarbon group which may be substituted" is a 5-nitro-2-pyridylamino WO 2006/135723 PCT/US2006/022416 -14- group,. 5-cyano-2-pyridylamino group, 2-pyrimidylamino group, 2-pyrazylamino group and the like. A substutent in the said "piperidinyl group which may be substituted" includes, for example, a Cx-6 alkyl group; a 5 hydroxymethyl group, "a C6_i4 aryl group which may be substituted" and "a heterocyclic group which may be substituted" exemplified in the said "amino group which may be mono- or di-substituted with C6-i4 aryl group which may be substituted or the heterocyclic group which may be substituted." The number of 10 substituents is, for example, 1 to 3. The said "substituent on the side chain of an amino acid" includes, for example, a hydrocarbon group which may be substituted, a hydroxyl group, a Ci_i0 alkoxy group which may be substituted with 1 to 3 halogen atoms (preferably fluorine) , an 15 acyl group, and amino group which may be substituted and the like. Herein, a hydrocarbon in the said "hydrocarbon group which may be substituted" includes, for example, a Ci-io alkyl group, a C3_ 12 cycloalkyl group, a C2~io alkenyl group, a C3_i2 cycloalkenyl 20 group and the like. The hydrocarbon group may have 1 to 3 substituents at substitutable positions, and such substituents include, for example, an amino group, a Ci_6 alkyl-carbonylamino group (preferably, acetylamino group), a hydroxyl group, a Ci_6 alkoxy 25 group, a heterocyclic group (preferably, pyridyl group) and the like. The said "acyl group" is preferably a nitrogen-containing heterocyclic-carbonyl group which may be substituted. The "nitrogen-containing heterocyclic which may be substituted" 30 includes nitrogen-containing heterocycles ((preferably, pyridine, pyridazine, pyrimidine, pyrazine, imidazole, pyrazole, thiazole, isothiazole, oxazole, isooxazole, etc.) which may have 1 to 3 substituents selected from, for example, a halogen atom (preferably, fluorine, chlorine, bromine), a cyano group, a WO 2006/135723 PCT/US2006/022416 -15- nitro goup, a Ci_6 alkyl group (e.g., trifluoromethyl group) which may be substituted with 1 to 3 halogen atoms (preferably fluorine), a Ci-6 alkoxy group, an amino group which may be mono-or di-substituted with Ci_6 alkyl group, a hydroxyl group, a 5 carboxy group and a Ci-e alkyl-oxycarbonyl group. A substituent in the said "amino group which may be substituted" includes a Ci_6 alkyl group, etc. which may have 1 torn 3 substituents selected from, for example, a carboxyl group, a carbamoyl group, a Ci-e alkyl-oxycarbonyl group and a nitrogen-10 containing heterocyclic group (preferably, pyridyl). These substituents may be coupled with a hydroxyl group, a carboxyl group, an amino group and the like which is on the side chain of an amino acid. A suitable example of the compound represented by formula (II) 15 includes N-(N'-substituted glycyl)-2-cyano-pyrrolidine derivatives such as (2 S)-l-{{{2-[(5-cyanopyridine-2- yl)amino]ethyl}amino}acetyl}-2-cyano-pyrrolidine (DPP-728) (described in WO 98/19998) represented by the formula: 20 < 2 S)-1-{[(3-hydroxy-l-adamantyl)amino]acetyl}-2-cyano- pyrrolidine (l-[(3-Hydroxy-adamant-l-ylamino)-acetyl]- pyrrolidine-2(S)-carbonitrile) (also known as LAF237 or vildagliptin)(described in WO 00/34241 represented by the formula: 25 H 9 9* l5 WO 2006/135723 PCT/US2006/022416 -16- (2S)-l-{{{2-[(pyrimidine-2-ylpiperidine-4-yl}amino}-acetyl-2-cyano-pyrrolidine (described in WO 02/30890). (2S) -1-{{{2-[(pyridine-2-yl)amino]ethyl}amino}acetyl}-2-cyano-pyrrolidine and (S)—1—{1—[5-(N,N'-dimethylaminosulfonyl)-2-5 pyridylamino]-2-methyl-propylamino}acetyl-2- pyrrolidinecarbonitrile (K-361) (described in WO 02/51836); thiazoline or pyrrolidine derivatives such as L-threo-isoleucylthiazoline (P32/98), L-allo-isolencylthiazoline, L-threo-isoeuculpryrrolidine, L-allo-isoleucylpyrrolidine and L-10 valylpyrrolidine (described in WO 01/72290) represented by the formula derivatives described in WO 01/55105. Preferably, (S,S)-1- (2-15 amino-3,3-dimethylbutylyl)-2,5-dihydro-lH-pyrrole-2-carbonitrile. (4) Heterocyclic compounds described in WO 02/02560. Preferably, 7-benzyl-8-[6-hydroxymethyl)-1,4-diazepam-l-yl]-1,3-diraethyl-3, 7-dihydropurine-2, 6-dione. 20 (5) Pyrrolidine derivatives of a condensed ring with cyclopropane described in WO 01/68603. Preferably, (IS,3S,5S)-2-[(2S)-2-amino-3,3-dimethylbutyryl]-3-cyano-2-azabicyclo[3,1,0]hexane. (6) Proline derivatives described in WO 02/14271. Preferably, 25 (2 S)-1-[(2S,4S)-4-(3-chloro-4-cyanophenyl)amino-2- pyrrolidinylcarbonyl]-2-cyanopyrrolidine. (7) Cyanopyrrolidine derivatives described in WO 02/38541. Preferably, (2S,4S)-1-[(2S,3S)-2-amino-3-methyl-pentanoyl]-2-cyano-4-fluoropyrrolidine, (2S,4S)-2-cyano-4-fluoro-1-[(1- 30 hydroxymethyl)cyclopentylamino]acetypyrrolidine, and (2S,4S)-2- o CH '3 (3) N-substituted 2-cyanopyrrole and 2-cyanopyrroline WO 2006/135723 PCT/US2006/022416 -17- cyano-4-fluoro-l-[(l-hydroxy-3-adamanylamino]acetylpyrrolidine. (8) Compounds such as P93/01 described in WO 02/02560, WO 03/055881, WO 03/040174, WO 03/037327, WO 03/035057, .WO 03/035067, WO 03/024942, WO 03/024965, WO 03/004498, WO 5 03/004496, WO 03/000250, WO 03/002530, WO 03/002531, WO 03/002553, WO 03/000180, WO 03/000181, EP 1258476, WO 02/51836, WO 02/68420, US 6,432,969, etc. (9) Another preferred DPP-4 inhibitor is the compound BMS-477118 disclosed in WO 2001068603 or U.S. Patent No. 6,395,767 10 (compound of example 60) also known as is (IS,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.I3'7]dec-l-yl)-1-oxoethyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, benzoate (1:1) as depicted in Formula M of the patent application WO 2004/052850 on page 2, and the corresponding free base, (IS,3S,5S)-2-[ (2S)-15 2-amino-2- (3-hydroxy-tricyclo [3. 3.1.13'7] dec-l-yl) -1-oxoethyl] -2-azabicyclo-[3.1.0]hexane-3-carbonitrile (M*) and its monohydrate (M") as depicted in Formula M of the patent application WO 2004/052850 on page 3. The compound BMS-477118 is also known as saxagliptin. 20 (10) Another preferred inhibitor is the compound GSK23A disclosed in WO 03/002531 (example 9) also known as (2S,4S)- 1-((2R)-2-Amino-3-[(4-methoxybenzyl)sulfonyl]-3-methylbutanoyl)-4-fluoropyrrolidine-2-carbonitrile hydrochloride. (11) Other preferred DPP-IV inhibitors are described in the 25 patent application WO 03/004498 especially examples 1 to 33 and most preferably the compound of the formula F F MK-0431 WO 2006/135723 PCT/US2006/022416 -18- described by the example 7 and also known as MK-0431 or Sitagliptin (INN). (12) Other preferred DPP-IV inhibitors are described in the patent applications WO 2004/037169 especially those described 5 in the examples 1 to 48 and WO 02/062764 especially the described examples 1 to 293, even preferred are the compounds 3-(aminomethyl)-2-isobuthyl-l-oxo-4~phenyl-l,2-dihydro-6-isoquinolinecarboxamide and 2-{[3-(aminomethyl)-2-isobuthyl-4-phenyl-l-oxo-1,2-dihydro-6-isoquinolyl]oxy}acetamide described 10 on page 7 and also in the patent application W02004/024184 especially in the reference examples 1 to 4. Specific examples of hydroxypropyl methylcellulose include: Metholose SB-4 (commercial name, Shinetsu Chemical Industry Co. Ltd. - made) (viscosity of 2 wt.% aqueous solution at 20°C: 15 about 4 mPa*s), TC-5 RW (commercial name, Sinetsu Chemical Industry Co. Ltd. - made) (viscosity of 2 wt.% aqueous solution at 20°C: about 6 mPa-s), TC-5 S (commercial name, Shinetsu Chemical Industry Co. Ltd. - made) (viscosity of 2 wt.% aqueous solutionat 20°C: about 15 mPa*s), Metholose 60SH-50 (commercial 20 name, Shinetsu Chemical Industry Co. Ltd. - made) (viscosity at 20°C: about 50 mPa-s), Metholose 65SH-50 (commercial name, Shinetsu Chemical Industry Co. Ltd. -made) (viscosity of 2 wt.% aqueous solution at 20°C: about 50 mPa-s), Metholose 90SH-100 (commercial name, Shinetsu Chemical Industry Co. Ltd. - made) 25 (viscosity of 2 wt.% aqueous solution at 20°C: about 100 mPa-s), Metholose 90SH-100SR (commercial name, Shinetsu Chemical Industry Co. Ltd. - made) viscosity of 2 wt.% aqueous solution at 20°C: about 100 mPa*s), Metholose 65SH-400 (commercial name, Shinetsu Chemical Industry Co. Ltd. - made) (viscosity of 2 wt.% 30 aqueous solution at 2 00 C: 400 mPa*s), Metholose 65SH-1500 (commercial name, Shinetsu Chemical Industry Co. Ltd. - made) (viscosity of 2 wt.% aqueous solution at 20°C: about 1500 mPa-s), Metholose 65SH-4000 (commercial name, Shinetsu Chemical Industry Co. Ltd. - made) (viscosity of 2 wt.% aqueous at 20°C: 35 about 1000 mPa-s), Metholose 65SH-1000 (commercial name, WO 2006/135723 PCT/US2006/022416 -19- . Shinetsu Chemical Industry Co. Ltd. - made) (viscosity of 2 wt.% aqueous solution at 20 °C: about 1000 mPa-s), Metholose 90SH-1000 (commercial name, Shinetsu Chemical Industry Co. Ltd.. -made) (viscosity of 2 wt.% aqueous solution at 20°C: 4000 5 mPa*s), Metholose 90SH 1000SR (commercial name, Shinetsu Chemical Industry Co. Ltd. - made) (viscosity of 2 wt.% aqueous solution at 20 °C: about 4000 mPa-s), Metholose 90SH-30000 (commercial name, Shinetsu Chemical Industry Co. Ltd. - made) (viscosity of 2 wt.% aqueous solution at 20°C: about 30000 10 mPa*s), Metholose 90SH-100000 (commercial- name, Shinetsu Chemical Industry Co. Ltd. - made) (viscosity of 2 wt.% aqueous solution at 20°C: about 100000 mPa*s), and Metholose 90SH-100000SR (commercial name, Shinetsu Chemical Industry Co. Ltd. -made) (viscosity of 2 wt.% aqueous solution at 20 °C: about 15 100000 mPa■s). "Sustained release preparation" or "modified release preparation" herein means a preparation wherein "the elution rate of the drug at 30 min after starting the test" is less than 85% when conducting, for example, the Second , Method (paddle 20 method) of the Elution Test Method in Japan Pharmacopoeia using 900 mL of an appropriate test solution when the rotating counts of the drug in the preparation eluted by 100% into the test solution is below 1/3 the saturation solubility of the drug. Also, the conventional test solutions in the pharmaceutical 25 technical field, e.g., water, a butter solution and the like are used, "preparation" means a pharmaceutical formulation or unit dosage form e.g. tablet, granule. In addition, a preparation wherein the elution rate of a drug at 30 min after starting the test is not less than 85% when 30 conducing the Second Method (paddle method) of the Elution Test Method in Japan Pharmacopoeia under conditions similar to the above is referred to as an immediate release preparation in this specification. WO 2006/135723 PCT/US2006/022416 -20- Dosage forms or unit dosage forms of the present sustained release preparation include, for example, an oral formulation such as a tablet, capsule (including a microcapsule), granule, or powder; and a parenteral formulation such as a suppository 5 (e.g., rectal suppository, vaginal suppository, etc.), and these can be safely administered orally or parenterally, respectively. Of these forms, an oral formulation such as a tablet, capsule, or granule is preferred. The sustained release preparation of the invention can be 10 manufactured by mixing the DPP-IV inhibitor and hydrophilic polymer and molding them. Herein, the mixing and molding are performed according to conventional pharmaceutical methods. Also, when performing the said mixing and molding, a pharmacologically acceptable carrier may be used. 15 Herein, the pharmacologically acceptable carriers include different types of conventional organic or inorganic carrier substances, for example, excipients, lusters, binders, disintegrators, and the like as base materials for the preparation. Further, additives for a preparation such as 20 preservatives, antioxidants, coloring agents, and sweeteners may also be used as needed. When the DPP-IV inhibitor used in the sustained release preparation of the invention is basic, an organic acid may be added to regulate elution behavior of the sustained release 25 preparation. Generally, since solubility of a basic drug is greater in the acidic condition than in the neutral condition, the drug elution from the sustained release preparation may vary depending on the surrounding pH. In such a case, change of the drug elution property based on the surrounding pH can be reduced 30 by use of an organic acid. Since the pH in the body may vary in individual patients, reducing changes of the drug elution based on the surrounding pH is extremely significant for obtaining a uniform drug effect for various patients. WO 2006/135723 PCT/US2006/022416 -21- The organic acids include, for example, citric acid, tartaric acid, ascorbic acid, malic acid, fumaric acid, malonic acid, succinic acid, maleic acid, aspartic acid, glutamic acid, etc. Of these, citric acid, tartaric acid, ascorbic acid, etc. are 5 preferred. The sustained release preparation of the invention has less toxicity and fewer side effects, accordingly it can be administered to mammals (e.g. humans, bovines, horses, dogs, cats, monkeys, mice, and rats) as a preventative and therapeutic 10 agent for various diseases. The sustained release preparation of the invention may be used as a preventative and therapeutic agent, for example, for diseases such as diabetes (e.g. type 1 diabetes, type 2 diabetes, pregnancy diabetes), hyperlipidemia (e.g. 15 hypertriglyceridemia, hypercholesterolemia, hypoHDLemia, postprandial hyperlipidemia), arterial sclerosis, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG), Impaired Fasting Glycemia (IFG), and diabetic complications (e.g., neuropathy, nephropathy, retinopathy, cataract, 20 angiopathy of large, vessel, osteopenia, diabetic hyperosmolar coma, infectious diseases (e.g., respiratory infection, urinary tract infection, digestive system infection, dermal soft tissue infection, lower limb infection), diabetic gangrene, dry oral cavity, decrease of audition, cerebrovascular disease, 25 peripheral circulation disorder) and as an agent for reducing blood sugar and the like. The sustained release preparation of the invention may prevent Abnormal Tolerance, Impaired Fasting Glucose (IFG) or Impaired Fasting Glycemeia (IFG) from developing into diabetes. 30 Further, the sustained release preparation of the invention can be used to improve pancreatic ((3-cell) function, pancreatic (|3-cell) regeneration, acceleration of pancreatic ((3-cell) regeneration, etc. WO 2006/135723 PCT/US2006/022416 -22- Since the DPP-IV inhibitor is an agent accelerating glucose-depending insulin secretion which exhibits selectively-accelerating action on insulin secretion in a patient with high blood sugar (e.g., patients who have not less than 126 mg/dL of 5 blood sugar value at fasting or not less than 140 mg/dL of 2-hour value after 75 g Oral Glucose Tolerance Test (75 g OGTT)). The sustained release preparation of the invention is useful as a safe preventative and therapeutic agent for diabetes with less risk for blood vessel complication, induction of hypoglycemia, 10 etc., which are harmful effects of insulin. While the dosing amount of the sustained release preparation of the present invention varies depending on the subject, administration route, target disease, etc., for oral administration to an adult patient with diabetes, for example, a 15 single dose of the DPP-IV inhibitor, which is the active ingredient, should usually be about 0.01-100 mg/kg weight, preferably 0.05-30 mg/kg weight, more preferably 0.1-10 mg/kg weight, and ideally be administered once or twice a day. Preferably, the sustained release preparation should be 2 0 administered to continuously obtain DPP-IV inhibitory action in the living body during from before a meal to at least 2 hours after a meal (preferably 4 hours after a meal). The sustained release preparation's release duration of the DPP-IV inhibitor in the living body should preferably be 1 to 24 25 hours; more preferably, 2 to 14 hours. Usually, when using a DPP-IV inhibitor to prevent or treat diabetes, it is necessary to take the DPP-IV inhibitor before every meal since GLP-1, which is a substrate of DPP-IV, is secreted upon intake of food. However, since the sustained 30 release preparation of the invention can release the DPP-IV inhibitor over a long time, it exhibits sufficient inhibitory effect of DPP-IV, even when taken once a day. The sustained release preparation of the invention may be used in combination with drugs (hereinafter, referred to as WO 2006/135723 PCT/US2006/022416 -23- concomitant drugs) such as a therapeutic agent for diabetes, a therapeutic agent for diabetic complications, an antihyperlipidemia agent, a depressor, and anti-obesity agent, a diuretic, and an antithromotic agent. In this case, the 5 medication time of the sustained release preparation of the invention and the comcomitant drug is not limited. Thus, these may be simultaneously administered to a subject, or administered at a different time, respectively. Further, the sustained release preparation of the invention and the concomitant drug 10 may be administered as two preparations containing one active ingredient each, or administered as a single preparation containing both active ingredients. The dosing amount of the concomitant drug can be appropriately selected based on the dose clinically used. The ratio of the 15 sustained release preparation of the invention to the concomitant drug can be appropriately selected based on the subject, administration route, target disease, symptom, combination, etc. For example, when the subject is human, 0.01-100 parts by weight to 1 part by weight of the concomitant drug 20 , based on the DPP-IV inhibitor, which is an active ingredient of the sustained release preparation, may be used. The said therapeutic agents for diabetes (antidiabetic) include, for example, insulin preparations (e.g., animal insulin preparations extracted from the pancreas of a bovine or swine; 25 human insulin preparations synthesized in genetic engineering sing E. coli or yeast; zinc insulin; zinc protamine insulin; fragments or derivatives of insulin (e.g., INS-1, etc.)), insulin-resistance-improving agents (e.g. Pioglitazone hydrochloride, Lociglytazone (maleate), GI-262570, Reglixane 30 (JTT-501), Netoglitazone (MCC-555), YM-440, KRP-297, CS-011, FK-614, Ragaglitazar (NN-622), Tesaglitazar (AZ-242), DMS-298585, EML-16336, compounds described in WO 99/58510 (e.g., (E)—4—[4 — (5-methyl-2-phenyl-4-oxazolylmehtoxy)benzyloxyimino]-4-phenylbutyric acid)), PPARy agonist, PPARy antagonist, 35 PPARy/adual agonist, a-glucosidase inhibitors (e.g. Voglibose, WO 2006/135723 PCT/US2006/022416 -24- Acarbose, Migritol, Emiglytate, biguanide agents (e.g.', Phenformin, Metformin, Buformine or their salts) (e.g. hydrochloride, furmarate, succinate)), accelerators of insulin secretion (sulfonylurea agents (e.g., Tolbutamide, 5 Glibenclamide, Gliclazide, Chlorpropamide, Tolazamide, Acetohexamide, Glyclopyramide, Glymepyride, Glypizide, Glybuzole, etc.), Repaglinide, Senaglinide, Nateglinide, Mitiglinide or their calcium salt hydrates), GLP-1 receptor agonists (e.g., GLP-1, NN-2211, AC-2993 (exedin-4), BIM-51077, 10 Alb (8,35) h GLP-1 (7,37) NH2) , amyline agonists (e.g., Plamlintide, phosphotyrosine phosphatase inhibitors (e.g. vanadic acid), (33 agonists (e.g., CL-316243, • SR-58611-A, UL-TG-307, SB-226552, AJ-9677, BMS-196085, AZ40140), inhibitors of neosugar (e.g., glycogen phosphorylase ihnhibitor, glucose-6-15 phosphatase inhibitor, glucagon antagonist, somatostatin receptor agonist), sodium-glucose cotransporter (SGLT) inhibitors (e.g., T-1095), etc. The therapeutic agents for diabetic complications include inhibitors of aldose reductase (e.g., Tolrestat, Epalrestat, 20 Zenarestat, Zopolrestat, Minalrestat, Phydarestat, SNK-860, CT-112), neurotrophy factor and its increasing agents (e.g., NGF, NT-3, BDNF, accelerators of neurotrophin production/secretion (e.g., 4-(4-chlorophenyl)-2-(2-methyl-l-imidazolyl)-5-[3-(2- methylphenoxy)propyl]oxazole etc.)) described in WO 01/14372), 25 ACE inhibitors (e.g., ALT946, Pimagedine, N-phenacylthiazolium bromide (ALT7 66), (EXO-226), active oxygen-erasing agents (e.g., thiocitic acid), cerebrovascular dilators (e.g., Tiapride, Mexiletine). The anti-hyperdilidemia agents include statin compounds which 30 are inhibitors of cholesterol synthesis (e.g., Cerivastatin, Pravastatin, Simvastatin, Rovastatin, Atorvastatin, Fluevastatin, Itavastatin, or their salts (e.g., sodium salts)), inhibitors or squalene synthase (e.g., compounds described in WO 97/10224, for example, N-[[(3R,5S)-1- (3-acetoxy-2,2- 35 dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl-2-oxo-l,2,3,5- WO 2006/135723 PCT/US2006/022416 -25- terahydro-4,l-benzooxazepine-3-yl]acetyl]piperidine-4-azetic acid etc.), fibrate compounds (e.g., Benzafibrate, Clofibrate, Simfibrate, Clinofibrate), ACAT inhibitors (e.g., Avasimibe, Eflucimibe), anion exchange resins (e.g., Cholestyramine), 5 Probucol, nicotinic acid drugs (e.g., nicomol, niceritrol), ethyl icosapentoate, plant sterols (soysterol), Y_oryzanol' etc. The depressors include angiotensin converting enzyme inhibitors (e.g., Captropril, Enalapril, Delapril), angiotensin II antagonists (e.g., Candesartan, Cilexetil, Losartan, Eprosartan, 10 Valsartan, Telmisartan, Irbesartan, Tasosartin), calcium antagonists (e.g., Manidipine, Nifedipine, Amlodipine, Efonidipine, Nicardipine), potassium channel opening drugs(e.g., Levcromakalim, L-27152, AL671, NIP-121), Clonidine, etc. The anti-obesity agents include, for example, central anti-15 obesity agents (e.g., Dexphenfluramine, Phenfluramine, Phentelmine, Sibutramine, Anfepramone, Dexanfetamine, Mazindol, Phenylpropanolamine, Kobenzorex, pancreatic lipase inhibitors (e.g., Orlistat) , (33 agonists (e.g., CL 316243, SR-58611-A, UL- TG-307, SB-22 6552, AJ-9677, BMS-196085, AZ40140), peptidyl 20 anorectics (e.g., Leptin, Ciliary Neurotrophic Factor (CNTF)), cholecystokinin agonists (e.g., FPL-15849)), etc. The diruetics include, for example, xanthine derivative (e.g., sodium salicylate theobromine, calcium salicylate theobromine), thiazide preparations (e.g. ethiazide, cyclopentiazide, 25 trichlormethiazide, hydrochlorothiazide, hydroflumethiazide, bentylhydrochlorothiazide, penfluthizide, polythiaside, methichlothiazide), anti-aldosterone preparations (e.g., spylonoacetone, trimetellen), carbonic anhydrase inhibitors (e.g., acetazolamide), chlorbenzenesufonamide preparations 30 (e.g., chlortalidone, meflucide, idapamide), azocernide, isosorbide, ethacrynic acid, pyrcladnide, bromethanide, flocemide, etc. The antithrombotic agents include, for example, heparin (e.g., heparin sodium, heparin calcium, dalteparin sodium), warfarin WO 2006/135723 PCT/US2006/022416 -26- (e.gwarfarin potasium), antithrombin agents (e.g., aragatroban), thrombolytics (e.g. urokinase, tisokinase, alteplase, nateplase, monteplase, pamiteplase), platelet aggregation inhibitors (e.g., flolopidine hydrochloride, 5 cllostazol, ethyl icosapentoate, beraprost sodium, sarpogrelate hudrochloride), etc. The concomitant drugs are preferably insulin preparations, insulin-resistance improving agents, a-glucosidase inhibitors, biguanide agents, insulin secretion accelerators (preferably 10 sulonyl urea), etc. Further, the present invention relates to "a drug comprising a combination of two or more preparations with DPP-IV inhibitor and different releasing rates fo the DPP-IV inhibitor." Herein, "the DPP-IV inbibitor-containing preparation" may be any 15 preparation containing the DPP-IV inhibitor, either a sustained release or immediate release preparation. In addition, the release control mechanism of the DPP-IV inhibitor in the "DPP-IV inhibitor-containing preparation" has no particular limitations, and the preparation may be any that releases the DPP-IV 20, inhibitor; by passive diffusion accompanying degradation of the prepartion; by response to change of the surrounding pH; by the inner pressure of the swollen inside of the preparation caused by intake of the surrounding water; immediate release by the preparation's disintegration or dissolution, and the like. 25 Herein, "preparations that release the DPP-IV inhibitor by passive diffusion" include, for example, the sustained release preparation of the invention, (preferably, a matrix tablet using hydorphylic polymers (e.g., hyroxypropylmethylcellulose, hydroxypropylcellulose, and polyethyleneoxixde), a matrix tablet 30 using lipophilic base materials (e.g., carnauba wax, hydrogenated castor oil, hydrogenated rape oil, polyglycerin fatty acid esters), a tablet or a granule coated with sustained release base materials (e.g., cellulose polymers such as ethylcellulose, acrylic acid polymers such as aminoalkyl WO 2006/135723 PCT/US2006/022416 -27- methacrylate copolymer RS (Eudragit RS (commercial name, Rohm Pharma Co. Ltd. - made), ethyl acrylate-methyl methacrylate copolymer suspension (Eudragit NE (commercial name, Rohm Pharma Co., Ltd. - made), etc. 5 The "preparations that release DPP-IV inhibitor from the preparation by degradation of the preparation" include, for example, a capsule containing polyglycolated glycerides (e.g. GeiucirelO/13 (commercial name, GATTEFOSSE Co. Ltd. - made)), etc. 10 The "preparations that release DPP-IV inhibitor in response to change of the surrounding pH" include, for example, a tablet or granule coated with enteric base materials (acrylic acid polymers such as methacrylate copolymer (Eudragit L (commercial name, Rohm Pharma Co. Ltd. - made) ) , methacrylate copolymer LD 15 (Eudragit L-30D55 (commercial name, Rohm Pharma Co. Ltd. made)), methyacrylate copolymer S (Eudragit S (commercial name, Rohm Pharma Co. Ltd. - made)), etc. The "preparations that release DPP-IV inhibitor by the inner pressure of the swollen inside of the preparation caused by 20 intake of the surrounding water" include, for example an osmotic system, i.e., Concerta™ (Alza Co. Ltd., Fort Washington, PA), etc. The "preparations that release DPP-IV inhibitor immediately by the preparation's disintegration or dissolution" include, for 25 example, those that are obtained by mixing the DPP-IV inhibitor with a pharmacologically acceptable carrier and then carrying out molding. Herein, the pharmacologically acceptable carrier includes those similar to the sustained release preparation of the invention. Also, mixing and molding can be performed 30 according to conventional pharmaceutical techniques. The release control mechanism of the "two or more preparations containing DPP-IV inhibitors" constituting the present drug of the invention may be either same or different from each other. The "two ore more preparations containing DPP-IV inhibitors" may WO 2006/135723 PCT/US2006/022416 -28- be a single preparation or plural preparations independent to each other. The single preparation includes a single capsule containing two ore more preparations containing the DPP-IV inhibitor; a multi-layer tablet (preferably a 2-layer tablet) or 5 nucleated tablet having multiple release controlling parts, and the like. The present drug of the invention should preferably be composed of a combination of a sustained release preparation containing a DPP-IV inhibitor and an immediate release preparation containing 10 a DPP-IV inhibitor, and by adopting such a combination, the excellent DPP-IV inhibitory action can be obtained immediately after administration and be maintained over a long term. While the content of the DPP-IV inhibitor in the sustained release preparation containing a DPP-IV inhibitor varies 15 depending on the type of DPP-IV inhibitor, amount of preparation, etc., the content is, for example 20-30% by weight, preferably 25-35% by weight, and ideally 25% by weight. Dosage forms of the DPP-IV inhibitor-containing preparation are similar to those of the sustained release preparation of the 20 present invention. The present drug of the invention has lower toxicity and fewer side effects, accordingly it can be administered to mammals (e.g., humans, bovines, horses, dogs, cats, monkeys, mice, and rats) as preventative and therapeutic agents of various diseases 25 similarly to the said sustained release preparation of the invention. The dosage of the present drug of the invention may be combined with the two or more preparations containing DPP-IV inhibitors at administration. Such a dosage form includes, for example, 1) 30 administration as a single preparation of two ore more preparations containing DPP-IV inhibitors, 2) simultaneous administration as multiple preparations of two or more preparations containing DPP-IV inhibitors, 3) administration at WO 2006/135723 PCT/US2006/022416 -29- different times of multiple preparations of two or more preparations confining DPP-IV inhibitors, etc. While the dosing amount of the drug of the invention varies depending on the subject, administration route, target disease, 5 etc., when orally administering it to an adult patient with diabetes, for example, the usual does of DPP-IV inhibitor, which is the active ingredient should be about 0.01-100 mg/kg weight, preferably 0.5 mg/kg weight, more preferably .1-10 mg/kg weight, and these amounts should ideally be administered once or twice a 10 day. Preferably, the drug of the invention should be administered to continuously obtain action of the DPP-IV inhibitor in the living body from before a meal to at least 2 hours after a meal preferably to 4 hours after a meal. The present drug of the invention may be used in combination 15 with the concomitant drug similar to the case of the sustained release preparation of the present invention. The present invention further relates to "the release-controlled preparation containing the DPP-IV inhibitor, which may decrease DPP-IV activity in blood plasma by 10 to 90% (preferably, 10 to 20 85%) 1 hr after ' administration", "the release-controlled preparation containing the DPP-IV inhibitor which may decrease DPP-IV activity in blood plasma by 10 to 90% (preferably, 10 to 85%) 8 hrs after administration", "the release-controlled preparation confining the DPP-IV inhibitor which may decrease 25 DPP-IV activity in blood plasma by 10 5o 90% (preferably, 10 to 85%) 12 hrs after administration", "the release-controlled preparation containing the DPP-IV inhibitor, which may decrease DPP-IV activity in the blood plasma by 10 to 90% (preferably, 10 to 85% over 1 to 8 hrs after administration", "the release-30 controlled preparation containing the DPP-IV inhibitor, which may decrease DPP-IV activity in blood plasma by 10 to 90% (preferably, 10 to 85%) over 1 to 12 hrs after administration", and the like. WO 2006/135723 PCT/US2006/022416 -30- Herein, the blood plasma in "DPP-IV activity in blood plasma" means peripheral venous blood plasma. Although the DPP-IV activity and its decrease rate may vary depending on the type of blood plasma (e.g., venous, arterial' or portal blood plasma), 5 any release-controlled preparations belong to the present invention of "release-controlled preparation containing the DPP-IV inhibitor" as long as they can decrease DPP-IV activity in peripheral venous blood plasma by 10 to 90% (preferably 10 to 85%) . 10 The present invention of the release-controlled preparation containing the DPP-IV inhibitor can decrease DPP-IV activity in blood plasma by 10 to 90%, preferably 10 to 85%, more preferably 10 to 80%, most preferably 15 to 75%. The DPP-IV activity in blood plasma can be measured according 15 to, for example, "the method of Raymond et al., Diabetes, Vol. 47, p. 1253- 1258, 1998." As long as the said decrease rate of the DPP-IV activity in blood plasma is within normal errors, it may be different from the said values (10, 15, 75, 80, 85, 90%). Further, the decrease rate of the DPP-IV activity in blood 20 plasma may be different from the said values depending on the method of measuring DPP-IV activity in blood plasma. For example, if measuring conditions such as substrate type, substrate concentration, reaction time, diluted multiples of blood plasma, and the like of DPP-IV activity in blood plasma 25 are different from those in the method described in the - above literature, the decrease rate of the DPP-IV activity in blood plasma may be greater than those described above, for example, the value of 90% may' be over 95%. Among preparations containing the DPP-IV inhibitor of the 30 present invention, the "release-controlled preparation containing the DPP-IV inhibitor" of the present invention is a preparation wherein release of the DPP-IV inhibitor is controlled. WO 2006/135723 PCT/US2006/022416 -31- Such a preparation is preferably the inventive sustained release preparation. Also, among the drugs of the invention, "a drug comprising a combination of sustained release preparation containing a DPP-IV inhibitor and an immediate release 5 preparation containing a DPP-IV inhibitor" is preferable. The release-controlled preparation containing the DPP-IV inhibitor of the present invention has lower toxicity and fewer side effects, accordingly it can be administered to mammals (e.g., humans, bovines, horses, dogs, cats, monkeys, mice, and 10 rats) as preventative and therapeutic agents of various diseases similarly to the sustained release preparation of the invention. While the dosing amount of the release-controlled preparation containing the DPP-IV inhibitor of the present invention varies depending on he .subject, administration route, target disease, 15 etc., when orally administering it to an adult patient with diabetes, for example, the usual does of DPP-IV inhibitor, which is the active ingredient, should be about 0.01-100 mg/kg weight, preferably 0.05-30 mg/kg weight, more preferably 0.1-10 mg/kg weight, and ideally administered once or twice a day. 20 Preferably, the release-controlled preparation containing the DPP-IV inhibitor of the present invention should be administered so that the action of the DPP-IV inhibitor in the living body is continuously obtained from before a meal to at least about 2 hours after a meal (preferably 4 hours after a meal). 25 The release-controlled preparation containing the DPP-IV inhibitor of the present invention may be used in combination with a concomitant drug as in the case of the sustained release preparation of the invention. Specific examples of a microcrystalline cellulose include, for 30 example Avicel® PH102 and 101 (FMC Biopolymer, Philadelphia, PA) . Specific examples of a magnesium stearate include, for example Synpro® Magnesium Stearate NF-Vegetable Grade (Ferro Corp., Walton Hills, OH). WO 2006/135723 PCT/US2006/022416 -32- Specific examples of a lactose include, for example, Lactose DT and Lactose SD. In addition, tablets often contain a diluent or filler which are added to increase the bulk weight of the blend resulting in a 5 practical size for compression. One, two, three or more diluent and/or filler can be selected. Examples of pharmaceutically acceptable fillers and pharmaceutically acceptable diluents include, but are not limited to, confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, lactose, 10 mannitol, microcrystalline cellulose, powdered cellulose, sorbitol, sucrose and talc. The filler and/or diluent, e.g., may be present in an amount from about 15% to about 55% or from about 15% to about 45% by weight of the composition. Most preferably the above described compositions comprise one or two 15 fillers selected from microcrystalline cellulose such as Avicel PH 102 and lactose. Lubricants are typically added to prevent the tableting materials' from sticking to punches, minimize friction during tablet compression and allow for removal of the compressed 20 tablet from the die. Such lubricants are commonly included in the final tablet mix in amounts usually about or less than 1% by weight. The lubricant component may be hydrophobic or hydrophilic. Examples of such lubricants include stearic acid, talc and magnesium stearate. Magnesium stearate reduces the 25 friction between the die wall and tablet mix during the compression and ejection of the tablets. It helps prevent adhesion of tablets to the punches and dies. Magnesium stearate also aids in the flow of the powder in the hopper and into the die. It has a particle size range of 450-550 microns and a 30 density range of 1.00-1.80 g/mL. It is stable and does not polymerize within the tableting mix. The preferred lubricant, magnesium stearate is also employed in the formulation. Preferably, the lubricant is present in the tablet formulation in an amount of from about 0.25% to about 6%; also preferred is 35 a level of about 0.5% to about 4% by weight; and most preferably WO 2006/135723 PCT/US2006/022416 -33- from about 0.1% to about 1% by weight. Other possible lubricants include talc, polyethylene glycol, silica and hardened vegetable oils. In an optional embodiment of the invention, the lubricant is not present in the formulation, but 5 is sprayed onto the dies or the punches rather than being added directly to the formulation. While the present invention is described in more detail in the following Experimental Details, the present invention is not limited to these and the uses of the invention may be varied as 10 long as the scope is not exceeded. Embodiments of the Invention The subject invention provides a pharmaceutical tablet formulation (Formulation C) comprising per unit dosage form e.g. per tablet the following ingredients: (a) a DPP-IV inhibitor preferably vildagliptin, or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution, (c) and optionally a filler and/or a lubricant. The subject invention provides a pharmaceutical tablet formulation (Formulation D) comprising per unit dosage form e.g. per tablet the following ingredients: 25 (a) 10-50% preferably 15-35% by weight on a dry weight basis of a DPP-IV inhibitor preferably vildagliptin, or a pharmaceutically acceptable salt thereof as an active ingredient, (b) 20-60% preferably 30-50% by weight on a dry 30 weight basis of a hydroxypropyl methylcellulose with an apparent viscosity of 80,00-0 cP to 120, 000 cP (nominal value 100,000 cP) when present in a 1% solution, 15 20 WO 2006/135723 PCT/US2006/022416 -34- (c) and optionally a filler and/or a lubricant. The subject invention provides a pharmaceutical tablet formulation (Formulation E) comprising per unit dosage form e.g. per tablet the following ingredients: 5 (a) 10-50% preferably 15-35% by weight on a dry weight basis of a DPP-IV inhibitor preferably vildagliptin, or a pharmaceutically acceptable salt thereof as an active ingredient, (b) 20-60% preferably 30-50% by weight on a dry 10 weight basis of a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution; (c) a filler; and 15 (d) a lubricant. The subject invention provides a pharmaceutical tablet formulation (Formulation F) comprising per unit dosage form e.g. per tablet the following ingredients: (a) 10-50% preferably 15-35% by weight on a dry 20 weight basis of a DPP-IV inhibitor preferably vildagliptin, or a pharmaceutically acceptable salt thereof as an active ingredient, (b) 20-60% preferably 30-50% by weight on a dry weight basis of a hydroxypropyl methylcellulose 25 with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution; (c) 15-55% preferably 25-45% by weight on a dry weight basis of a pharmaceutically acceptable 30 filler; and optionally WO 2006/135723 PCT/US2006/022416 -35- (d) 0.1-10% preferably 0.1-3% by weight on a dry weight basis of a pharmaceutically acceptable lubricant. The subject invention provides a pharmaceutical tablet 5 formulation (Formulation G) comprising per unit dosage form e.g. per tablet the following ingredients: (a) 10-50% preferably 15-35% by weight on a dry weight basis of a DPP-IV inhibitor preferably vildagliptin, or a pharmaceutically acceptable 10 salt thereof as an active ingredient, (b) 20-60% preferably 30-50% by weight on a dry weight basis of a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% 15 solution; (c) 15-55% preferably 25-45% by weight on a dry weight basis of one or two pharmaceutically acceptable fillers selected from lactose and microcrystalline cellulose ; and optionally 20 (d) 0.1-10% preferably 0.1-3% by weight on a dry weight basis of a pharmaceutically acceptable lubricant such as magnesium stearate. The subject invention provides a pharmaceutical tablet formulation (Formulation H) comprising per unit dosage form e.g. 25 per tablet the following ingredients: (a) 10-50% preferably 15-35% by weight on a dry weight basis of a DPP-IV inhibitor preferably vildagliptin, or a pharmaceutically acceptable salt thereof as an active ingredient, 30 (b) 20-60% preferably 30-50% by weight on a dry weight basis of a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 WO 2006/135723 PCT/US2006/022416 -36- cP (nominal value 100,000 cP) when present in a 1% solution; (c) 25-40% by weight on a dry weight basis of one or two pharmaceutically acceptable fillers 5 selected from lactose and microcrystalline cellulose ; and optionally (d) 0.1-10% preferably 0.1-3% by weight on a dry weight basis of a pharmaceutically acceptable lubricant. 10 A pharmaceutical tablet formulation as described herein wherein the filler is selected from lactose and microcrystalline cellulose. A pharmaceutical tablet formulation (Formulation I) as described herein comprising at least two fillers preferably lactose and 15 microcrystalline cellulose. In an embodiment, the lactose is present in an amount from 1 to 8% preferably 1 to 5% by weight and microcrystalline cellulose is present in an amount from 25 to 35% by weight A pharmaceutical tablet formulation (Formulation J) as described 20 herein wherein 20-30% by weight on a dry weight basis of a DPP-IV inhibitor especially LAF237 is contained in the formulation. A pharmaceutical tablet formulation (Formulation K) as described herein wherein the hydroxypropyl methyl cellulose is present in an amount from 34% to 46% preferably from 38% to 42% by weight. 25 A formulation as described herein wherein the compound (DPP-IV inhibitor) is 1-[(3-hydroxy-adamant-l-ylamino)-acetyl]- pyrrolidine-2(S)-carbonitrile (LAF237 or vildagliptin). A formulation (Formulation L), capsule, granule or tablet as 30 described herein wherein vildagliptin (LAF237) is a crystalline form of vildagliptin (crystal "Form A"), characterized by an X-ray diffraction pattern with peaks at about 16.6°, 17.1°, 17.2° WO 2006/135723 PCT/US2006/022416 -37- +/- 0.3 degrees 2-theta or characterized by an X-ray diffraction pattern with peaks at about 12.0°, 13.5°, 16.6°, 17.1°, 17.2°, 20.1°, 22.5°, 27.4°, 28.1° , +/- 0.3 degrees 2-theta. Such a crystal form is described in the International patent 5 application No. PCT/US2006/001473 The term "vildagliptin" covers any crystalline form, preferably the crystal form "A" of vildagliptin. The subject invention provides a pharmaceutical tablet formulation comprising per unit dosage form e.g. per tablet the 10 following ingredients: (a) a compound as an active ingredient, wherein the compound has a formula: R(CH2)n' 15 wherein R is substituted adamantyl and n is an integer from 0 to 3, preferably vildagliptin; or a pharmaceutically acceptable salt thereof; (b) a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP 20 (nominal value 100,000 cP) when, present in a 1% solution; (c) a microcrystalline cellulose; and (d) a magnesium stearate. In an embodiment, relative to the weight of the formulation: 25 (a) the compound e.g. vildagliptin is present in an amount from 20% to 30% by weight; (b) the hydroxypropyl methylcellulose is present in an amount from 30% to 50% by weight; WO 2006/135723 PCT/US2006/022416 -38- (c) the microcrystalline cellulose is present in an amount from 25% to 35% by weight; and (d) the magnesium stearate is present in an amount from 0.1% to 3% by weight. 5 In another embodiment, relative to the weight of the formulation: (a) the compound e.g. vildagliptin is present in an amount of about 25% by weight; (b) the hydroxypropyl methylcellulose is present in an 10 amount of about 40% by weight; (c) the microcrystalline cellulose is present in an amount of about 30% by weight; and (d) the magnesium stearate is present in an amount of about 1% by weight. 15 In a further embodiment, the tablet formulation further comprising a lactose. In an embodiment, the lactose is present in an amount from 1% to 8% by weight. In an additional embodiment the lactose is in an amount of about 4% by weight. In an embodiment, the DPP-IV inhibitor is selected from [S]-l-2 0 [2-(5-cyano-2-pyridinylamino)ethylamino]acetyl-2-pyrolidine carbonitrile monohydrochloride, vildagliptin, L-threo-isoleucyl thiazolidine, Sitagliptin, Saxagliptin , 3-(aminomethyl)-2-isobuthyl-l-oxo-4-phenyl-l,2-dihydro-6-isoquinolinecarboxamide and 2-{[3-(aminomethyl)-2-isobuthyl-4-phenyl-l-oxo-l,2-dihydro-25 6-isoquinolyl]oxy}acetamide and optionally pharmaceutical salts thereof. In an embodiment, the compound (DPP-IV inhibitor) is 1—[2—[(5— cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano(S)-pyrrolidone or a pharmaceutically acceptable salt thereof. 30 In a preferred embodiment, the invention concerns a composition or unit dosage form as described herein wherein the compound (DPP-IV inhibitor) is vildagliptin or a salt thereof. WO 2006/135723 PCT/US2006/022416 -39- In yet another embodiment, the compound vildagliptin is present in the formulation or a pharmaceutically acceptable salt thereof. The subject invention also provides a pharmaceutical tablet 5 formulation (Formulation A) , comprising per 400 mg tablet the following ingredients: (a) vildagliptin or a pharmaceutically acceptable salt thereof in an amount of about 100 mg; (b) a hydroxypropyl methylcellulose in an amount of 10 about 160 mg, wherein the hydroxypropyl methylcellulose has an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution; (c) a microcrystalline cellulose in an amount of 120 15 mg ; (d) a lactose in an amount of about 16 mg; and (e) a magnesium stearate in an amount of 4 mg. The subject invention also provides a pharmaceutical tablet formulation (Formulation B) , comprising per 600 mg tablet the 20 following ingredients: (a) vildagliptin or a pharmaceutically acceptable salt thereof in an amount of about 150 mg; (b) a hydroxypropyl methylcellulose in an amount of about 240 mg, wherein the hydroxypropyl 25 methylcellulose has an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution; (c) a microcrystalline cellulose in an amount of 180 mg; 30 (d) a lactose in an amount of about 24 mg; and (e) a magnesium stearate in an amount of 6 mg. WO 2006/135723 PCT/US2006/022416 -40- In an embodiment, the pharmaceutical tablet formulation comprises combining the ingredients in the amounts recited above. The subject invention also provides a method of inhibiting 5 dipeptidyl peptidase IV activity in a subject comprising administering to the subject an amount of the above-mentioned pharmaceutical tablet formulations effective to inhibit the activity of dipeptidyl peptidase IV in the subject. In an embodiment, the subject is a human being. 10 The subject invention also provides a method of treating a condition alleviated by dipeptidyl peptidase IV inhibition in a subject suffering from the condition comprising administering to the subject a therapeutically effective dose of any of the herein-mentioned pharmaceutical tablet formulations, unit dosage 15 forms e.g. capsule, tablet, compressed table, direct compressed tablets, granule. The subject invention also covers the use of any of the herein-mentioned pharmaceutical tablet formulations, unit dosage forms e.g. capsule, tablet, compressed table, direct compressed 20 tablets, granule, for the manufacture of a medicament for the treatment of a condition alleviated by dipeptidyl peptidase IV inhibition in a subject suffering from the condition comprising administering to the subject a therapeutically effective dose of any of the above-mentioned pharmaceutical tablet formulations. 25 The subject invention also covers the use of any of the herein-mentioned pharmaceutical tablet formulations, unit dosage forms e.g. capsule, tablet, compressed table, direct compressed tablets, granule for the treatment of a condition alleviated by dipeptidyl peptidase IV inhibition in a subject suffering from 30 the condition comprising administering to the subject a therapeutically effective dose of any of the above-mentioned pharmaceutical tablet formulations. Preferably the condition alleviated by dipeptidyl peptidase IV inhibition is selected from non-insulin-dependent diabetes WO 2006/135723 PCT/US2006/022416 -41- mellitus, arthritis, obesity, allograft transplantation, calcitonin-osteoporosis, Heart Failure, Impaired Glucose Metabolism), IGT (Impaired Glucose Tolerance), neurodegenerative diseases such as Alzheimer's and Parkinson disease, modulating 5 hyperlipidemia, modulating conditions associated with hyperlipidemia or for lowering VLDL, LDL and Lp(a) levels, cardiovascular or renal diseases e.g. diabetic cardiomyopathy, left or right ventricular hypertrophy, hypertrophic medial thickening in arteries and/or in large vessels, mesenteric 10 vasculature hypertrophy, mesanglial hypertrophy, neurodegenerative disorders and cognitive disorders, to produce a sedative or anxiolytic effect, to attenuate post-surgical catabolic changes and hormonal responses to stress, to reduce mortality and morbidity after myocardial infarction, the 15 treatment of conditions related to the above effects which may be mediated by GLP-1 and/or GLP-2 levels. In an , embodiment, the condition is non-insulin-dependent diabetes mellitus. In another embodiment, the condition is obesity, arthritis, or 20 osteoporosis. In a further embodiment, the subject is a human being. The subject invention further provides a method of treating a condition alleviated by dipeptidyl peptidase IV inhibition in a subject suffering from the condition comprising administering to 25 subject a therapeutically effective amount of any of the above-mentioned pharmaceutical tablet formulations in combination with a therapeutically effective dose of an anti-diabetic or arthritis drug. In an embodiment, the subject is a human being. 30 The subject invention also provides a pharmaceutical tablet formulation comprising per unit dosage form e.g. per tablet the following ingredients: (a) a compound as an active ingredient, wherein the compound has a formula: WO 2006/135723 PCT/US2006/022416 -42- O CN H \ .N R(CH2)„ wherein R is substituted adamantyl and n is an integer from 0 to 3; or a pharmaceutically acceptable salt thereof; and 5 (b) a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution. In one embodiment, the herein described pharmaceutical tablet 10 formulations also contains a filler. In one embodiment, the filler is lactose. In another embodiment, the filler is microcrystalline cellulose. In a further embodiment the filler is microcrystalline cellulose and lactose. In another embodiment, the herein described pharmaceutical 15 tablet formulations also contains a lubricant. In one embodiment, the lubricant is preferably magnesium stearate. In yet another embodiment, relative to the weight of the formulation, the hydroxypropyl methyl cellulose is present in the herein described formulations in an amount from 30% to 50% 20 by weight. In an embodiment, the hydroxypropyl methyl cellulose is present in the herein described formulations in an amount from 34% to 46% preferably from 38% to 42% by weight. In a further embodiment, the present invention also concerns 25 the herein described pharmaceutical tablet formulation, wherein in the unit dosage form, the ratio of the weight of vildagliptin to the weight of hydroxypropyl methylcellulose is of 0.16 to 2.5, preferably 0.3 to 1.16 or 0.4 to 1. WO 2006/135723 PCT/US2006/022416 ' »» »*• 'wv- htuvf <w5- {■' vumv & vv5w<w^ -43- Preferably the herein expressed ratios or % are expressed on a dry weight basis. In a further embodiment, the present invention also concerns the herein described pharmaceutical tablet formulation, wherein 5 in the unit dosage form, vildagliptin is present in an amount of 100 mg to 200 mg, preferably 100 mg, 150 mg, or 200 mg or the corresponding amount of any of its salt. The herein described pharmaceutical tablet formulation can also be used in any unit dosage form, for example, an oral 10 formulation such as a tablet (including multilayer tablets), capsule (including a microcapsule, capsules containing several e.g. two compartments), granule, or powder; or a parenteral formulation such as a suppository or any other pharmaceutical delivery system. Preferably the herein described pharmaceutical 15 tablet formulation are used in the form of capsule, granule or tablet. In a further embodiment, the present invention also concerns a pharmaceutical multilayer tablet wherein the herein described pharmaceutical tablet formulation, represents one of the tablet 20 layers. This can be done as a multilayer tablet (one over the other) or as a coating one layer surrounding the other one. Preferably the present invention also concerns a pharmaceutical multilayer tablet wherein the herein described pharmaceutical tablet formulation, represents one layer and a formulation 25 comprising a further active ingredient represent the second layer and/or third layer. Preferably the further active ingredient is a glitazone (e.g. pioglitazone or rosiglitazone) or metformin. Preferably the further or second layer is an immediate release formulation. The herein described 30 pharmaceutical tablet formulation can represent the middle layer and the immediate release formulation comprising a further active ingredient can represent the two external layers. The herein described pharmaceutical tablet formulation can represent the central layer and the immediate release formulation WO 2006/135723 PCT/US2006/022416 -44- comprising a further active ingredient can represent the surrounding coating layer. In a further embodiment, the present invention also concerns a pharmaceutical tablet obtained by compression of the herein 5 described pharmaceutical tablet formulation. In a further embodiment, the present invention also concerns the above pharmaceutical tablet obtained by compression of the herein described pharmaceutical tablet formulation, wherein the herein described pharmaceutical tablet formulation is subject to 10 roller compaction before compression into tablet. In a further embodiment, the present invention also concerns the above pharmaceutical tablet, wherein the hardness range is of between 10 to 13Kp for the 100 mg vildagliptin tablet, and between 11 to 25Kp for the 150 mg vildagliptin tablet. 15 In the development of the herein described pharmaceutical compositions, the applicant has discovered that the compressed tablets especially direct compressed tablet is particularly advantageous if the particles comprising the DPP-IV inhibitor especially LAF237, have a particle size distribution of less 20 than 250 jam preferably between 10 to 250 jam. Thus in a further embodiment the present invention concerns the herein described pharmaceutical tablet formulations, wherein the dispersion contains particles comprising DPP-IV inhibitor preferably LAF237, in free form or in acid addition salt form, 25 and wherein at least 60%, preferably 80% and most preferably 90% of the particle size distribution in the formulation is less than 250 ]um or preferably between 10 to 250 ]im. The present invention concerns the herein described pharmaceutical tablet formulations, wherein the dispersion 30 contains particles comprising DPP-IV inhibitor preferably LAF237, in free form or in acid addition salt form, and wherein at least 60%, preferably 80% and most preferably 90% of the WO 2006/135723 PCT/US2006/022416 -45- particle size distribution in the formulation is greater than 10 jam. The term "wherein at least 60%, preferably 80% and most preferably 90%" means at least 60%, preferably at least 80% and 5 most preferably at least 90%. The term "wherein at least at least 25%, preferably 35% and most preferably 45%" means at least 25%, preferably at least 35% and most preferably at least 45%. In particular the present invention concerns the herein 10 described pharmaceutical tablet formulations, wherein the dispersion contains particles comprising DPP-IV inhibitor preferably LAF237, in free form or in acid addition salt form, and wherein at least 25%, preferably 35% and most preferably 45% of the particle size distribution in the formulation is between 15 50 to 150 jum. The selected particle size distribution provides an acceptable dissolution profile, as well as acceptable degrees of hardness, friability, Tablet breaking strength, Dispersion Quality and resistance to chipping, as well as a proper disintegration time, 20 required flow and cohesive properties neces.sary to obtain an acceptable solid dosage form, Improved manufacturing robustness, required compactibility. Particle size of drug, e.g. LAF237 particles size, is controlled 25 by crystallisazion, drying and/or milling/sieving (non limiting examples are described below). Particle size can also be comminuted using roller compaction and milling/sieving. Producing the right particle size is well known and described in the art such as in "Pharmaceutical dosage forms: volume 2, 2nd 30 edition, Ed.: H.A.Lieberman, L.Lachman, J.B.Schwartz (Chapter 3: SIZE REDUCTION)". WO 2006/135723 PCT/US2006/022416 -46- Multiple particle sizes have been studied and it has been discovered that the herein described specific size range provides unexpected good results for direct compaction. PARTICLE SIZE DISTRIBUTION ESTIMATION BY ANALYTICAL SIEVING: 5 Particle size distribution is measured using Sieve analysis, Photon Correlation Spectroscopy or laser diffraction (international standart ISO 13320-1), or electronic sensing zone, light obstruction, sedimentation or microscopy which are procedures well known by the person skilled in the art. Sieving 10 is one of the oldest methods of classifying powders by particle size distribution. Such methods are well known and described in the art such as in any analytical chemistry text book or by the United State Pharmacopeia's (USP) publication USP-NF (2004 -Chapter 786 - (The United States Pharmacopeial Convention, Inc., 15 Rockville, MD)) which describes the US Food and Drug Administration (FDA) enforceable standards. The used techniques are e.g. described in Pharmaceutical dosage forms: volume 2, 2nd edition, Ed.: H.A.Lieberman, L.Lachman, J.B.Schwartz is a good example. It also mentions (page 187) additional methods: 20 Electronic sensing zone, light obstruction, air permeation, sedimentation in gas or liquid. In an air jet sieve measurement of particle size, air is drawn upwards, through a sieve, from a rotating slit so that material on the sieve is fluidised. At the same time a negative pressure 25 is applied to the bottom of the sieve which removes fine particles to a collecting device. Size analyses and determination of average particle size are performed by removal of particles from the fine end of the size distribution by using single sieves consecutively. See also "Particle Size 30 Measurement", 5th Ed. , p 178, vol. 1; T. Allen, Chapman & Hall, London, UK, 1997, for more details on this. For a person skilled in the art, the size measurement as such is thus of conventional character. WO 2006/135723 PCT/US2006/022416 -47- The herein described formulations can also be in the form of a layer in a multi or 2-layer tablet. The herein described formulations can also be in the form of capsules, tablets, compressed tables, direct compressed tablets, 5 granules. The DPP-IV inhibitor compounds especially vildagliptin, useful in this invention are hygroscopic, presents stability problems, and are not inherently compressible into tablets. Consequently, there is a need to provide a free-flowing and cohesive 10 composition capable of being compressed,' preferably directly, into strong tablets with an acceptable in vitro dissolution, pharmacokinetic, and pharmacodynamic profile. The Paddle method to measure the drug dissolution rate (% of release) is used with 1000ml of 0.01N HC1. Such methods are well 15 known and described in the art such as in any analytical chemistry text book or by the United State Pharmacopeia's (USP) publication USP-NF (2004 - Chapter 711) which describes the US Food and Drug Administration (FDA) enforceable standards. In a further embodiment, the present invention concerns two 20 pharmaceutical tablet formulations comprising respectively 100 mg or 150 mg of vildagliptin and providing a vildagliptin release profile particularly adapted for providing an improved pharmacokinetic profile. The resulting pharmacokinetic profile result in an improved treatment quality of the patient. 25 Thus, the present invention concerns; 1) a pharmaceutical tablet formulation comprising 100 mg of vildagliptin or a salt thereof, preferably compressed in the form of a sustained release tablet, wherein; - between 10% and 16% preferably between 11% and 15% of 30 vildagliptin is released after 0.5 hour, • - between 18% and 24% preferably between 19% and 23% of vildagliptin is released after 1 hour, WO 2006/135723 PCT/US2006/022416 w uauo/ icr-!tz.Ta. -48- - between 30% and 36% preferably between 31% and 35% of vildagliptin is released after 2 hours, - between 46% and 52% preferably between 47% and 51% of vildagliptin is released after 4 hour, 5 - between 58% and 64% preferably between 59% and 63% of vildagliptin is released after 6 hours, - between 67% and 73% preferably between 68% and 72% of vildagliptin is released after 8 hours, - between 74% and 80% preferably between 75% and 79% of 10 vildagliptin is released after 10 hours, - between 80% and 86% preferably between 81% and 85% of vildagliptin is released after 12 hours, - between 91% and 97% preferably between 92% and 96% of vildagliptin is released after 18 hours, 15 - between 95% and 100% preferably between 96% and 100% of vildagliptin is released after 24 hours. 2) a pharmaceutical tablet formulation comprising 150 mg of vildagliptin or a salt thereof, preferably compressed in the 20 form of a sustained release tablet, wherein; - beitween 3.8% and 9.8% preferably between 4.8% and 8.8% of vildagliptin is released after 0.25 hour, - between 8.1% and 14.1% preferably between 9.1% and 13.1% of vildagliptin is released after 0.5 hour, 25 - between 14.7% and 20.7% preferably between 15.7% and 19.7% of vildagliptin is released after 1 hours, - between 25.3% and 31.3% preferably between 26.3% and 30.3% of vildagliptin is released after 2 hour, - between 40.9% and 46.9% preferably between 41.9% and 45.9% of 30 vildagliptin is released after 6 hours, WO 2006/135723 PCT/US2006/022416 -49- - between 62.1% and 68.1% preferably between 63.1% and 67.1% of vildagliptin is released after 8 hours, - between 76.5% and 82.5% preferably between 77.5% and 81.5% of vildagliptin is released after 10 hours, 5 - between 83.5% and 89.5% preferably between 84.5% and 88.5% of vildagliptin is released after 12 hours, - between 88.5% and 94.5% preferably between 89.5% and 93.5% of vildagliptin is released after 18 hours. For the above described two pharmaceutical tablet formulations 10 the Paddle method to measure the drug dissolution rate (% of release)has been used. Preferably the above described two pharmaceutical tablet formulations comprise a hydroxypropyl methylcellulose, preferably between 20% and 60%, between 30% and 50% by weight on 15 a dry weight basis of a hydroxypropyl methylcellulose. Preferably the above described two pharmaceutical tablet formulations comprise a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution, preferably between 20 20% and 60%, or between 30% and 50% by weight on a dry weight basis of a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution. Preferably the above described two pharmaceutical tablet 25 formulations comprising 150 mg or 100 mg of vildagliptin are in the form of a tablet or multilayer tablet. Preferably the above described two pharmaceutical tablet formulations comprising 150 mg or 100 mg of vildagliptin comprise any of the herein described pharmaceutical tablet 30 formulations. Preferably the above described two pharmaceutical tablet formulations are in the form of a tablet obtained by compression of a pharmaceutical tablet formulation as herein described, WO 2006/135723 PCT/US2006/022416 -50- wherein .the pharmaceutical tablet formulation is subject to roller compaction before compression into tablet. Preferably the above described pharmaceutical tablets comprise 100 mg of vildagliptin or a salt thereof wherein the tablet 5 hardness range is of between 10 to 13Kp. Preferably the above described pharmaceutical tablets comprise 150 mg of vildagliptin or a salt thereof wherein the tablet hardness range is of between 11 to 25Kp. In a further aspect, the present invention concerns the use of 10 the herein described pharmaceutical formulations, capsules, tablets, compressed tables, direct compressed tablets, granules for the treatment of conditions, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, allograft transplantation, calcitonin-osteoporosis, Heart Failure, 15 Impaired Glucose Metabolism), IGT (Impaired Glucose Tolerance), neurodegenerative diseases such as Alzheimer's and Parkinson disease, modulating hyperlipidemia, modulating conditions associated with hyperlipidemia or for lowering VLDL, LDL and Lp(a) levels, cardiovascular or renal diseases e.g. diabetic 20 cardiomyopathy, left or right ventricular hypertrophy, hypertrophic medial thickening in arteries and/or in large vessels, mesenteric vasculature hypertrophy, mesanglial hypertrophy, neurodegenerative disorders and cognitive disorders, to produce a sedative or anxiolytic effect, to 25 attenuate post-surgical catabolic changes and hormonal responses to stress, to reduce mortality and morbidity after myocardial infarction, the treatment of conditions related to the above effects which may be mediated by GLP-1 and/or GLP-2 levels. In a further aspect, the present invention concerns a method of 30 treating conditions, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, allograft transplantation, calcitonin-osteoporosis, Heart Failure, Impaired Glucose Metabolism), IGT (Impaired Glucose Tolerance), neurodegenerative diseases such as Alzheimer's and Parkinson disease, modulating WO 2006/135723 PCT/US2006/022416 «• *'• »• 1«» «■' (W ""(J" -51- hyperlipidemia, modulating conditions associated with hyperlipidemia or for lowering VLDL, LDL and Lp(a) levels, cardiovascular or renal diseases e.g. diabetic cardiomyopathy, left or right ventricular hypertrophy, hypertrophic medial 5 thickening in arteries and/or in large vessels, mesenteric vasculature hypertrophy, mesanglial hypertrophy, neurodegenerative disorders and cognitive disorders, to produce a sedative or anxiolytic effect, to attenuate post-surgical catabolic changes and hormonal responses to stress, to reduce 10 mortality and morbidity after myocardial infarction, the treatment of conditions related to the above effects which may be mediated by GLP-1 and/or GLP-2 levels, comprising administering to a warm-blooded animal in need thereof a therapeutically effective amounts of a pharmaceutical tablet 15 formulation, capsules, tablets, compressed tables, direct compressed tablets, granules as herein described. Preferably, the condition is selected from such as non-insulin-dependent diabetes mellitus, obesity, calcitonin-osteoporosis, Heart Failure, Impaired Glucose Metabolism, IGT (Impaired 20 Glucose Tolerance) , neurodegenerative diseases, such as Alzheimer's and Parkinson disease, modulating hyperlipidemia, modulating conditions associated with hyperlipidemia or for lowering VLDL, LDL and Lp(a) levels. In a further aspect, the present invention concerns a process 25 for preparing a tablet, in unit dosage form, which comprises: (a) blending a pharmaceutical tablet formulation as described herein above, (b) compressing the formulation prepared during step (a) to form the compressed tablet in unit 30 dosage form. In a further aspect, the present invention concerns a process for preparing a tablet, in unit dosage form, which comprises: (a) blending a pharmaceutical tablet formulation as described herein above, WO 2006/135723 PCT/US2006/022416 -52- (b) roller compacting the formulation prepared during step (a) (c) . compressing the formulation prepared during step (b) to form the compressed tablet in unit 5 dosage form. In a further aspect, the present invention concerns a process for preparing a tablet, in unit dosage form, which comprises: (d) blending a pharmaceutical tablet formulation as described herein above, 10 (e) roller compacting the formulation prepared during step (a) with a compaction force comprised between 10 and 16 KN or any of the herein described preferred compaction forces, (f) compressing the formulation prepared during 15 step (b) to form the compressed tablet in unit dosage form. In another embodiment, the present invention provides a 100 mg vildagliptin sustained release solid oral pharmaceutical dosage form which is; 20 i-1) a solid oral pharmaceutical dosage form comprising about 100 mg of vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 15.8 ng/mL +/- 25 6.85 ng/mL to about 173 ng/mL +/- 52 ng/mL between about 0.5 and about 16 hours following oral administration of said dosage form in a patient not treated with vildagliptin before said administration and wherein patient is under fasted conditions (day 1 of the above described study) , and/or 30 i-2) a solid oral pharmaceutical dosage form comprising about 100 mg of vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma WO 2006/135723 PCT/US2006/022416 -53- concentration of vildagliptin ranging from about 26.3 ng/mL +/-13.1 ng/mL to about 175 ng/mL +/- 62.5 ng/mL between about 0.5 and about 16 hours following administration of said dosage form on day 9 in a patient treated with said dosage form once a day 5 since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the above described study) , and/or i—3) a solid oral pharmaceutical dosage form comprising about 100 mg of vildagliptin free base, or a respective amount of a 10 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 26.9 ng/mL +/-14.1 ng/mL to about 186 ng/mL +/- 80.6 ng/mL between about 0.5 and about 16 hours following administration of said dosage form 15 on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions (day 10 of the above described study) , and/or ii-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a 20 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC(0-inf) of vildagliptin ranging from about 1073 to about 1825 ng*h/mL i.e. 1449 ng*h/mL +/- 376 ng*h/mL following oral administration of said dosage form , in a patient not treated with vildagliptin 25 before said administration and wherein said patient is under fasted conditions (day 1 of the above described study) , and/or ii-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, 30 said dosage form providing an arithmetic mean AUC(o-24) of vildagliptin ranging from about 1001 to about 1977 ng*h/mL i.e. 1489 ng*h/mL + /- 488 ng«h/mL following oral administration of said dosage form , on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has WO 2006/135723 PCT/US2006/022416 -54- been served an ADA breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the above described study) , and/or ii-3) a solid oral dosage form comprising about 100 mg 5 vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC(0-24) of vildagliptin ranging from about 1103 to about 2173 ng»h/mL i.e. 1638 ng*h/mL +/- 535 ng*h/mL following oral administration of 10 said dosage form , on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions (day 10 of the above described study) , and/or iii-1) a solid oral dosage form comprising about 100 mg 15 vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 3.61 hr +/- 1.44 hr following oral administration of said dosage form , in a patient not treated 20 with vildagliptin before said administration and wherein said patient is under fasted conditions (day 1 of the above described study) , and/or iii-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a 25 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 2.59 hr +/- 1.4 hr following oral administration of said dosage form , on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has 30 been served an ADA breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the above described study) , and/or iii-3) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a WO 2006/135723 PCT/US2006/022416 -55- pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 3.74 hr +/- 1.44 hr following oral administration of said dosage form , on day 10 in a patient 5 treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions (day 10 of the above described study) , and/or iv-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a 10 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 205 ng/ml +/- 47 ng/ml following oral administration of said dosage form , in a patient not treated with vildagliptin before said administration and wherein said 15 patient is under fasted conditions (day 1 of the above described study) , and/or iv-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, 20 said dosage form providing an arithmetic mean Cmax of vildagliptin of 200 ng/ml +/- 64 ng/ml following oral administration of said dosage form , on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes 25 of the morning administration of said dosage form (day 9 of the above described study) , and/or iv-3) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, 30 said dosage form providing an arithmetic mean Craax of vildagliptin of 245 ng/ml +/- 68 ng/ml following oral administration of said dosage form , on day 10 in a patient treated with said dosage form once a day since day 1 and wherein WO 2006/135723 PCT/US2006/022416 -56- said patient is under fasted conditions (day 10 of the above described study) , and/or v-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a 5 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean % inhibition of DPP-IV activity over 24 hours of 85.64% +/- 12.7 6% following oral administration of said dosage form , in a patient not treated with vildagliptin before said administration and 10 wherein said patient is under fasted conditions (day 1 of the above described study) , and/or v-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, 15 said dosage form providing an arithmetic mean % inhibition of DPP-IV activity over 24 hours of 87.78% +/- 16.37% following oral administration of said dosage form , on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes 20 of the morning administration of said dosage form (day 9 of the above described study) , and/or v-3) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, 25 said dosage form providing an arithmetic mean % inhibition of DPP-IV activity over 24 hours of 90.20% +/- 7.35% following oral administration of said dosage form , on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions (day 10 of the above 30 described study) , and/or vi-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as WO 2006/135723 PCT/US2006/022416 -57- substantially depicted in figure 24, following oral administration of said dosage form , in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions (day 1 of the above described 5 study) , and/or vi-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as 10 substantially depicted in figure 25, following oral administration of said dosage form , on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the 15 above described study) , and/or vi-3) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as 20 substantially depicted in figure 26, following oral administration of said dosage form , on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, (day 10 of the above described study). 25 Preferably the 100 mg vildagliptin sustained release solid oral pharmaceutical dosage form comprises a hydroxypropyl methylcellulose, preferably between 20% and 60%, between 30% and 50% or between 34% and 46% by weight on a dry weight basis of a hydroxypropyl methylcellulose. 30 Preferably the 100 mg vildagliptin sustained release solid oral pharmaceutical dosage form comprises a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution, preferably between 20% and 60%, or between 30% and 50% WO 2006/135723 PCT/US2006/022416 -58- or between 34% and 46% by weight on a dry weight basis of a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution. 5 Preferably the 100 mg vildagliptin sustained release solid oral pharmaceutical dosage form comprises any of the hereinabove described pharmaceutical tablet formulations. Preferably the 100 mg vildagliptin sustained release solid oral pharmaceutical dosage form comprises a pharmaceutical tablet 10 formulations selected from the herein described formulations A, B, C, D, E, F, G, H, I, J, K, or L. In another embodiment,- the present invention provides a 150 mg vildagliptin sustained release solid oral pharmaceutical dosage form which is; 15 i-a) a solid oral pharmaceutical dosage form comprising about 150 mg of vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 30.7 ng/mL +/-20 21.9 ng/mL to about 223 ng/mL +/- 77.3 ng/mL between about 0.5 and about 16 hours following oral administration of said dosage form in a patient not treated with vildagliptin before said administration and wherein patient is under fasted conditions (day 1 of the above described study), and/or 25 i-b) a solid oral pharmaceutical dosage form comprising about 150 mg of vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 48.7 ng/mL +/-30 25.8 ng/mL to about 223 ng/mL +/- 99.7 ng/mL between about 0.5 and about 16 hours following administration of said dosage form on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA WO 2006/135723 PCT/US2006/022416 -59- breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the above described study) , and/or i-c) a solid oral pharmaceutical dosage form comprising about 150 mg of vildagliptin free base, or a respective amount of a 5 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 44.6 ng/mL +/-28.5 ng/mL to about 2 63 ng/mL +/- 8 4.4 ng/mL between about 0.5 and about 16 hours following administration of said dosage form 10 on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions (day 10 of the above described study) , and/or ii-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a 15 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC(0-inf) of vildagliptin ranging from about 1346 to about 3196 ng*h/mL i.e. 2271 ng*h/mL +/- 925 ng*h/mL following oral administration of said dosage form , in a patient not treated with vildagliptin 20 before said administration and wherein said patient is under fasted conditions (day 1 of the above described study) , and/or ii-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, 25 said dosage form providing an arithmetic mean AUC(0-24) of vildagliptin ranging from about 1277 to about 3207 ng»h/mL i.e. 2242 ng*h/mL +/- 965 ng*h/mL following oral administration of said dosage form , on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has 30 been served an ADA breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the above described study) , and/or ii-c) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a WO 2006/135723 PCT/US2006/022416 -60- pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC(o_24) of vildagliptin ranging from about 1643 to about 3273 ng*h/mL i.e. 2458 ng*h/mL +/- 815 ng*h/mL following oral administration of 5 said dosage form , on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions (day 10 of the above described study) , and/or iii-a) a solid oral dosage form comprising about 150 mg 10 vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 3.57 hr +/- 1.17 hr following oral administration of said dosage form , in a patient not treated 15 with vildagliptin before said administration and wherein said patient is under fasted conditions (day 1 of the above described study) , and/or iii-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a 20 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 2.87 hr +/- 1.59 hr following oral administration of said dosage form , on day 9 in a patient treated with said dosage form once a day since day 1 and wherein 25 said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the above described study) , and/or iii-c) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a 30 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean traax of vildagliptin of 4.13 hr +/- 1.24 hr following oral administration of said dosage form , on day 10 in a patient treated with said dosage form once a day since day 1 and wherein WO 2006/135723 PCT/US2006/022416 -61- said patient is under fasted conditions (day 10 of the above described study) , and/or iv-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a 5 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 257 ng/ml +/- 59 ng/ml following oral administration of said dosage form , in a patient not treated with vildagliptin before said administration and wherein said 10 patient is under fasted conditions (day 1 of the above described study) , and/or iv-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, 15 said dosage form providing an arithmetic mean Cmax of vildagliptin of 272 ng/ml +/- 111 ng/ml following oral administration of said dosage form , on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes 2 0 of the morning administration of said dosage form (day 9 of the above described study) , and/or iv-c) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, 25 said dosage form providing an arithmetic mean Cmax of vildagliptin of 308 ng/ml +/- 91 ng/ml following oral administration of said dosage form , on day 10 in a patient treated with said dosage■form once a day since day 1 and wherein said patient is under fasted conditions (day 10 of the above 30 described study) , and/or v-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean % inhibition of WO 2006/135723 PCT/US2006/022416 -62- DPP-IV activity over 24 hours of 90.04% +/- 11.91% following oral administration of said dosage form , in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions (day 1 of the 5 above described study) , and/or v-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean % inhibition of 10 DPP-IV activity over 24 hours of 90.4% +/- 17.50% following oral administration of said dosage form , on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the . 15 above described study) , and/or v-c) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean % inhibition of 20 DPP-IV activity over 24 hours of 91.64% +/- 8.47% following oral administration of said dosage form , on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions (day 10 of the above described study) , and/or 25 vi-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as substantially depicted in figure 24, following oral 30 administration of said dosage form , in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions (day 1 of the above described study) , and/or WO 2006/135723 PCT/US2006/022416 -63- vi-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as 5 substantially depicted in figure 25, following oral administration of said dosage form , on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the 10 above described study) , and/or vi-c) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as 15 ■ substantially depicted in figure 26, following oral administration of said dosage form , on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions (day 10 of the above described study). 20 Preferably the 150 mg vildagliptin sustained release solid oral pharmaceutical dosage form comprises a hydroxypropyl methylcellulose, preferably between 20% and 60%, between 30% and 50% or between 34% and 46% by weight on a dry weight basis of a hydroxypropyl methylcellulose. 25 Preferably the 150 mg vildagliptin sustained release solid oral pharmaceutical dosage form comprises a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120, 000 cP (nominal value 100, 000 cP) when present in a 1% solution, preferably between 20% and 60%, or between 30% and 50% 30 or between 34% and 46% by weight on a dry weight basis of a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution. Received at IPONZ 15 April 2011 -64- Preferably the 150 mg vildagliptin sustained release solid oral pharmaceutical dosage form comprises any of the hereinabove described pharmaceutical tablet formulations. 5 Preferably the 150 mg vildagliptin sustained release solid oral pharmaceutical dosage form comprises a pharmaceutical tablet formulations selected from the herein described formulations A, B, C, D, E, F, G, H, I, J, K or L. Any of the above described 100 mg or 150 mg vildagliptin 10 sustained release solid oral pharmaceutical dosage form wherein; i) the formulation is a matrix formulation containing a pharmaceutically acceptable hydrophilic polymer which can retard diffusion of vildagliptin, ii) the solid oral pharmaceutical dosage form is a compressed 15 tablet, and optionally iii) the elution rate of vildagliptin at 30 minutes after starting the test is less than 30% when conducting the Paddle method. 2 0 "Pharmaceutically acceptable hydrophilic polymer which can retard diffusion of an active ingredient" are known in the art e.g. Hydroxypropyl-methylcelluose. Although some of the examples may fall outside the scope of the claims, these examples serve to further illustrate the present 25 invention and are retained for clarity and completeness. WO 2006/135723 PCT/US2006/022416 -65- 10 Experimental Details I. Pharmaceutical Development and Manufacture A. Selected Formulation and Process Composition A dry blend process with roller compaction was developed for direct compression, as shown in the process flow diagram (Figure 1) . Two dosage strengths, 100 mg and 150 mg of vildagliptin, were selected for further development and are shown in Tables 2-1 and 2-2. This process utilizes a common dry blend for the two strengths. Table 2-1 Composition per lOOmg dosage form unit for Market Formulation containing 40% HPMC K100M Product name: vildagliptin Tab 100mg Basis number/ Variant: 3768652.003 Shape /size /color /imprint: 11mm FFBE (round)/white to off-white Global material no. Component Composition per unit (mg) Testing monograph Function 146082 103266 103282 151580 100217 Total weight vildagliptin Microcrystalline cellulose, PH102 Lactose, anhydrous DT Hydroxypropyl- methylcelluose K100M Magnesium stearate 100 120 16 160 4 400 Novartis Ph. Eur., NF Ph. Eur., NF Ph. Eur., NF Ph. Eur., NF Drug Substance Tablet filler Tablet filler Controlled release polymer Tablet lubricant 15 20 WO 2006/135723 PCT/US2006/022416 -66- Table 2-2 Composition per 150mg dosage form unit for Market Formulation containing 40% HPMC K100M Product name: vildagliptin Tab 150mg Basis number/Variant: 6001732.001 Shape /size /color /imprint: 17 x 6.7mm ovaloid/white to off-white Global material Component Composition Testing Function no. per unit (mg) monograph 146082 vildagliptin 150 Novartis Drug Substance 103266 Microcrystalli ne cellulose, PH102 180 Ph. Eur., NF Tablet filler 103282 Lactose, anhydrous DT 24 Ph. Eur., NF Tablet filler 151580 Hydroxypropy I- methylcelluos eK100M 240 Ph. Eur., NF Controlled release polymer 100217 Magnesium stearate 6 Ph. Eur., NF Tablet lubricant Total weight 600 Process 5 The selected manufacturing process is shown in figure 2-1. B. Formulation and Alternative Variants Several formulation variants were evaluated as potential clinical service forms (CSF) in order to provide the requested release rate profile. The term clinical service forms (CSF) 10 means a formulation adapted for administration to a patient. Several types of release rate profiles were studied; in particular a slow and fast. The profile rate was determined by the amount and type of polymer selected and/or tablet technology. The Market Formulation (MF) selected is a specific 15 slow release rate profile (see Section I.A.)particularly adapted for a once a day dosage regimen and production of compressed tablets. Examples of the fast release rate formulations are shown in Tables 2-3 to 2-7 and alternate formulations with slow release profiles are shown in Tables 2-8 to 2-10. WO 2006/135723 PCT/US2006/022416 -67- Table 2-3 Composition per lOOmg dosage form unit for fast release profile containing 20% HPMC K100LV Product name: vildagliptin Tab 100mg Basis number/ Variant: 3768652.001 Shape /size /color /imprint: /white to off-white Global material Component Composition Testing Function no. per unit (mg) monograph 146082 vildagliptin 100 Novartis Drug Substance 103266 Microcrystalli ne cellulose, PH102 170 Ph. Eur., NF Tablet filler 103282 Lactose, anhydrous DT 46 Ph. Eur., NF Tablet filler 151580 Hydroxypropy I- methylcelluos e K100LVP 80 Ph. Eur., NF Controlled release polymer 100217 Magnesium Stearate 4 Ph. Eur., NF Tablet lubricant Total weight 400 Table 2-4 Composition per 200mg dosage form unit for fast release profile 5 containing 20% HPMC K100LV Product name: vildagliptin Tab 200mg Basis number/ Variant: 3768660.002 Shape /size /color /imprint: /white to off-white Global material Component Composition Testing Function no. per unit (mg) monograph 146082 vildagliptin 200 Novartis Drug Substance 103266 Microcrystalli 340 Ph. Eur., NF Tablet filler ne cellulose, ' PH102 103282 Lactose, anhydrous DT 92 Ph. Eur., NF Tablet filler 151580 Hydroxypropy I- methylcelluos e K100LVP 160 Ph. Eur., NF Controlled release polymer 100217 Magnesium 8 Ph. Eur., NF Tablet lubricant Stearate Total weight 800 WO 2006/135723 PCT/US2006/022416 -68- Table 2-5 Composition per 200mg dosage form unit for fast release profile containing 20% HPMC E10M Product name: vildagliptin Tab 200mg Basis number/ Variant: Shape /size /color/imprint: /white to off-white Global material no. Component Composition per unit (mg) Testing monograph Function 146082 vildagliptin 200 Novartis Drug Substance 103266 Microcrystalli ne cellulose, PH102 242 Ph. Eur., NF Tablet filler 103282 Lactose, 32 Ph. Eur., NF Tablet filler anhydrous DT 151580 Hydroxypropy I- methylcelluos e, E10M 120 Ph. Eur., NF Controlled release polymer 100217 Magnesium stearate 6 Ph. Eur., NF Tablet lubricant Total weight 600 The concentration of HPMC E10M was varied from 20% to 35% to match the target release rate profile. A combination of HPMC E10 5 (15%) and HPMC K100M (10%) was also evaluated for release rate. Table 2-6 Composition per lOOmg dosage form unit for fast release profile containing X% polyox Product name: vildagliptin Tab 100mg Basis number/ Variant: Shape /size /color /imprint: /white to off-white Global material Component Composition Testing Function no. per unit (mg) monograph 146082 vildagliptin 100 Novartis Drug Substance 103266 Microcrystalli ne cellulose, PH102 170 Ph. Eur., NF Tablet filler 103282 Lactose, anhydrous DT Polyox ?? 46 Ph. Eur., NF Tablet filler Controlled release polymer 100217 Magnesium Stearate 4 Ph. Eur., NF Tablet lubricant Total weight 400 WO 2006/135723 PCT/US2006/022416 -69- Bi-layer tablet technology was evaluated using a 50mg immediate release (IR) tablet in one layer, and an 150mg MR as the second layer as shown in Table 2-7. 5 Table 2-7 Composition per 200mg dosage form unit for bi-layer tablet containing HPMC K100M Product name: vildagliptin Tab 200mg Basis number/ Variant: NA Shape /size /color /imprint: /white to off-white Global material Component Composition Testing Function no. per unit (mg) monograph First Layer (IR) 146082 vildagliptin 50 Novartis Drug Substance 103266 Microcrystalli 96 Ph. Eur., NF Tablet filler ne cellulose, PH102 103282 Lactose, 48 Ph. Eur., NF Tablet filler anhydrous DT Explotab 4 Ph. Eur., NF Disintegra nt Magnesium 2 Ph. Eur., NF III Lubricant Stearate Total 200 Second Layer (MR) 146082 1-1(3- 150 Novartis Drug Hydroxy- Substance adamant-1- ylamino)- acetyl]- pyrrolidine- 2(S)- carbonitrile 151580 Hydroxypropy 130 Ph. Eur., NF Controlled I- release methylcelluos polymer e K100M 103266 Microcrystalli 120 Ph. Eur., NF Tablet filler ne cellulose, PH102 103282 Lactose, 46 Ph. Eur., NF Tablet filler anhydrous DT 100217 Magnesium 4 Ph. Eur., NF Tablet stearate lubricant Total weight 450 WO 2006/135723 PCT/US2006/022416 -70- The amount of vildagliptin DS and HPMC K100M were varied in each layer to provide a suitable release rate profile. For example, the DS was varied from 25mg to 50mg (immediate release layer) and 150mg to 175mg (modified release layer). The amount of HPMC 5 K100M was varied from 29% to 40% (modified release layer). Another exploratory slow release variant was the HPMC concentration was reduced to 30%, with and without roller compaction, as shown in Tables 2-8 and 2-9 . This change did not have an effect on the dissolution profile. However, 30% HPMC 10 K100M exhibited a lower flow quality, 0.21 and 0.37, for both non-roller compacted and roller compacted material, respectively, when compared to 40% HPMC K100M. Filming was also observed during compression with 30% HPMC K100M. Table 2-8 Composition per lOOmg dosage form unit with 30% HPMC Product name: vildagliptin Tab 100mg Basis number/ Variant: NA Shape /size /color /imprint: 11 mm FFBE (round)/white to off-white Global material Component Composition Testing Function no. per unit (mg) monograph 146082 vildagliptin 100 Novartis Drug Substance 103266 Microcrystalli ne cellulose, PH102 120 Ph. Eur., NF Tablet filler 103282 Lactose, anhydrous DT 58 Ph. Eur., NF Tablet filler 151580 Hydroxypropy I- methylcelluos eK100M 120 Ph. Eur., NF Controlled release polymer 100217 Magnesium stearate 4 Ph. Eur., NF Tablet lubricant Total weight 400 15 20 WO 2006/135723 PCT/US2006/022416 Table 2-9 Composition per 150mg dosage form unit with 30% HPMC Product name: vildagliptin Tab 150mg Basis number/ Variant: NA Shape /size /color /imprint: 17 x 6.7mm ovaloid/white to off-white Global material Component Composition Testing Function no. per unit (mg) monograph 146082 vildagliptin 150 Novartis Drug Substance 103266 Microcrystalli ne cellulose, PH102 180 Ph. Eur., NF Tablet filler 103282 Lactose, anhydrous DT 24 Ph. Eur., NF Tablet filler 151580 Hydroxypropy I- methylcelluos e K100M 180 Ph. Eur., NF Controlled release polymer 100217 Magnesium stearate 6 Ph. Eur., NF Tablet lubricant Table 2-10 Composition per 200mg dosage form unit for slow release profile containing 40% HPMC K100M Product name: vildagliptin Tab 200mg Basis number/ Variant: 3768660.003 Shape /size /color /imprint: /white to off-white Global material Component Composition Testing Function no. per unit (mg) monograph 146082 vildagliptin 200 Novartis Drug Substance 103266 Microcrystalli ne cellulose, PH102 240 Ph. Eur., NF Tablet filler 103282 Lactose, anhydrous DT 32 Ph. Eur., NF Tablet filler 151580 Hydroxypropy I- methylcelluos e K100M 320 Ph. Eur., NF Controlled release polymer 100217 Magnesium Stearate 8 Ph. Eur., NF Tablet lubricant Total weight 800 5 Selection of Formulations for the Manufacture of Clinical Variants The four formulations selected for further clinical evaluation comprised of both types of release rate profiles (slow and fast) WO 2006/135723 PCT/US2006/022416 -72- ■ at two dosage strengths (lOOmg and 200iug) . The batch size was 4,000 tablets (or 3.1kg). Pre-compression was required to meet the hardness and/or- friability requirements. The slow formulation contained 40% HPMC K100M as shown in Tables 2-1 and 5 2-10. The fast formulation contained 20% HPMC K100 LVP as shown in Tables 2-3 and 2-4. Table 2-11 Clinical batch summary Rate Profile Strength Polymer Compositi on KN Number/ Variant Batch Number Slow 100mg 40% HPMC K100M Table 2-1 3768652.00 2 AEUS200200 81 Slow 200mg 40% HPMC K100M Table 2-10 3768660.00 3 AEUS200200 83 Fast 100mg 20% HPMC K100 LVP Table 2-3 3768652.00 1 AEUS200200 80 Fast \ 200mg 20% HPMC K100LVP Table 2-4 3768660.00 2 AEUS200200 82 Formulation Rationale 1-[(3-Hydroxy-adamant-l-ylamino)-acetyl]-pyrrolidine-2(S) -10 carbonitrile i.e. vildagliptin DS (Drug Substance) is highly water soluble (up to 125mg/mL) and so requires polymers that can act as substantial diffusion barriers for a dramatic reduction in drug dissolution and diffusion. A once a day MR dosage form is likely to require a significant level of polymer load for 15 retarding drug diffusion. During the development, the applicant has selected monolithic formulation with low risk for dose dumping, eliminating coating technologies in favor of a matrix formulation. After intensive studies on compatibility, ability to retard diffusion pharmacokinetic and pharmacodynamic 20 studies, and regulatory acceptance requirements the applicant narrowed the polymer choice to hydrophilic polymers, especially hydroxpropyl methyl cellulose (HPMC). Major and Critical Findings During Formulation Development A critical excipient is the control release polymer, HPMC, as 25 the K100M grade. During the CSF development, various control WO 2006/135723 PCT/US2006/022416 -73- release polymers were evaluated alone, or in combination, in order to achieve the desired release profile. HPMC, K100M grade, provided- the best match to the desired release profile. The "slow" formulation was selected after evaluation in man. 5 As previously mentioned, pre-compression was utilized during the clinical batch manufacture. Experiments were conducted to further evaluate the CSF formulation and the need for pre-compression. The compression profile for the CSF formulation containing 40% 10 HPMC is shown in Figures 3 and 4. The data indicated that the compression profile and friability could be improved with pre-compression. Additional studies were conducted to improve the compression profile and to avoid the use of pre-compression. 15 As shown in Figure 5, 30% HPMC K100M was evaluated to improve the compression profile. The effect of tablet dwell time was simultaneously evaluated at speeds from 40 to 80rpm. It was determined that an improvement in the compression profile was achieved using roller compaction. As shown in Figures 6 and 20 7, a Fitzpatrick (Chilsonator®, model IR220) was evaluated with the interim powder blend without the addition of magnesium stearate, at increasing compaction forces. As shown in Figures 8 and 9, the effect of roller compaction on the dissolution profile was studied with 40% HPMC K100M and 25 compared to the dissolution profile of the clinical batch. It was concluded that roller compaction did not impact the dissolution profile. The roller compaction process was scaled to a 50mm Bepex roller compactor using a linear relationship developed for a 50mm 30 Fitzpatrick roller compactor (in lb/in units, model IR520) and a 50mm Bepex ( in KN units) roller compactor. As shown in Figures 10 and 11, the effect of increasing compaction force was studied. It was concluded that the process was scaleable to a WO 2006/135723 PCT/US2006/022416 -74- Bepex roller compactor, and the tablet hardness was not significantly affected with increasing roller compaction force (13-31KN), and roller compactor roll speed (4-8rpm). Overview of Compositions Including CSF in Clinical Studies 5 See section "B. Formulation and Alternative Variants C. Manufacturing Process All variants were manufactured as detailed in the process flow chart shown in Figure 1, except variants without roller compaction. A batch size of up to 12 Kg was used. Drug substance 10 from lots; 0223007, 0223008, 0223009 were used for all batches manufactured Description and Assessment of the Processes Tested The effect of roller compaction was evaluated with 30% and 40% HPMC. Roller compaction was utilized to densify the powder blend 15 prior to compression. The effect of Fitzpatrick (Chilsonator®, model IR220) roller compactor at compaction forces from 500 to 10,000 lb/in on a powder blend containing 40% HPMC, are shown in Figures 12 and 13. The data indicated that with increasing roller compaction force, 20 led to a decrease in tablet hardness. As shown in Figure 14, roller compaction forces greater than 5,000 lb/in (or 43.75 KN) produced tablets with a compression profile worst than the CSF without roller compaction or pre-compression. The effect of roller compaction on tablet friability is shown in 25 Figure 14. Key Section Criteria and Rationale for Final Process The key criteria for the final process was based on the dissolution profile. Since a PK/safety study was conducted in vivo using the lOOmg, 150mg and 200mg tablets, the formulation 30 containing 40% HPMC K100M was desired. Roller compaction was added to the process to improve the compression profile. As shown in Figures 17 and 18, the dissolution profile for roller WO 2006/135723 PCT/US2006/022416 -75- compacted material did not differ from the CSF dissolution profile. The Japanese Ministry of Health has imposed 40mg/kg as a daily intake limit for HPMC K100M. It is not anticipated that the daily intake limits will become a regulatory hurdle for the 1-[(3-Hydroxy-adamant-l-ylamino)-acetyl]-pyrrolidine-2(S)-carbonitrile MF. The physical properties of the various powder blends are shown in Tables 2-12 and 2-13. Table 2-12 Physical properties of roller compacted powder blend (Fitzpatrick) Sample Roller Compaction Force (lb/in) [calculated KN] Powder Flow Quality Bulk Density/Tap (Sotax) Density (g/mL) TRD-1926-78 40% HPMC TRD-1971-53 40% HPMC TRD-1971-55 40% HPMC TRD-1926-79 30% HPMC TRD-1926-79 30% HPMC TRD-1926-01 40% HPMC TRD-1926-78 40% HPMC TRD-1926-01 40% HPMC TRD-1771-123B 40% HPMC TRD-1771-123C 40% HPMC NA NA NA NA 1,000 [8.75] 500 [4.37] 1,000 [8.75] 1,500 [13.1] 5,000 [43.75] 10,000 [87.5] 0.38 0.33 0.36 0.21 0.37 0.25 0.49 0.53 0.76 0.38/0.576 0.38/0.66 0.36/ 0.59 0.385/ 0.60 0.432/ 0.645 0.398/ 0.588 0.448/ 0.652 0.448/ 0.666 0.526/0.714 ND (not tabletable) 0.566/ 0.732 Avicel PH102 NA 0.64 0.29/ 0.35 10 WO 2006/135723 PCT/US2006/022416 -76- Table 2-13 Physical properties of roller compacted powder blend (Bepex) Sample Roller Compaction Force (Kn) [calculated lb/in] Roll Speed (rpm) Powder Flow Quality (Sotax) Bulk Density/Tap Density (g/mL) TRD-1926-78 40% HPMC TRD-1971-53 40% HPMC TRD-1971-55 40% HPMC TRD-1971-53C 40% HPMC TRD-1971-53A 40% HPMC TRD-1971-53B2 40% HPMC TRD-1971-55A 40% HPMC TRD-1971-55B 40% HPMC TRD-1971-55C 40% HPMC NA NA NA NA NA NA 13 [1500 lb/in] 22 [2500 lb/in] 31 [3500 lb/in] 13 13 13 Avicel PH102 NA NA 0.38 0.33 0.36 0.25 0.49 0.53 0.76 ND (not tabletable) 0.38/0.576 0.38/0.66 0.36/ 0.59 0.398/ 0.588 0.448/ 0.652 0.448/ 0.666 0.526/0.714 0.566/ 0.732 0.64 0.29/ 0.35 The use of roller compaction indicated an increase in the powder flow quality and an increase in bulk density. This was limited by the roller compaction force, where tablets from 5,000 lb/in and 10,000 lb/in force exhibited a poor friability of 0.6% and > 10%, respectively (lOOmg tablets). The effect of roller compaction on the sieve analysis is shown in Figures 19 and 20. All roller compacted material was screened using an 18 mesh screen. Selection of screen size as a means to WO 2006/135723 PCT/US2006/022416 -77- particle size control, and will be further evaluated during the Lab Phase FMI. Equipment Used Table 2-14 Process equipment Description Model Bin Blender Oscillating mill Roller compactor LB Bohle, 10L, 25L, 40L Ferwitt Fitzpatrick, Chilsonator, IR220 Roller Compactor Tablet Press Bepex, 50mm Manesty Beta Press, 16 sta. Statement on the Up-Scaling Potential and of the final process Robustness Table 2-15 IPC summary for vildagliptin lOOmg MR containing 40% HPMC with roller compaction (400mg tablet weight, 11mm FFBE) Sample Thickness (mm) IPC: 2.8-4.2mm Hardness (Kp) %Friability (100 drops) TRD-1926-78 1,000 lb/in RC (FP) 3.95 - 3.72 40 rpm: 11.5-13.2 60 rpm: 9.76-12.69 80 rpm: 9.76-12.84 40 rpm: < 0.5 60 rpm: < 0.5 80 rpm: < 0.5 TRD-1771-123A 1,000 lb/in RC (FP) 4.07 - 3.68 40 rpm: 8-18.3 40 rpm: < 0.5 TRD-1926-01A 500 lb/in RC (FP) 4.0-3.81 40 rpm: 9.3 -14.8 40 rpm: 0.1 TRD-1926-01B 1,500 lb/in RC (FP) 4.02-3.66 40 rpm: 7.6 - 19.9 40 rpm: 0.1 TRD-1771-31 Not RC 4.13-3.94 40 rpm: 5.1 -7.75 40 rpm: 6.3, capping 10 15 WO 2006/135723 PCT/US2006/022416 -78- Table 2-16 IPC summary for vildagliptin 150mg MR containing 40% HPMC with roller compaction (600mg tablet weight, 17 x 6.7mm ovaloid) Sample Thickness (mm) IPC: 2.8-4.2mm Hardness (Kp) %Friability (100 drops) TRD-1926-78 1,000 lb/in RC (FP) 40 rpm: 6.5 60 rpm: 6.4 80 rpm: 6.6 CO CO N-O O O CO CO CO I I I 40 rpm: 17.5 -60 rpm: 15.5-80 rpm: 11.2- 25.9 24.8 24.4 40 rpm: < 0.2 60 rpm: < 0.2 80 rpm: < 0.2 TRD-1771-123A 1,000 lb/in RC (FP) 6.4-5.84 40 rpm: 12.3 — 30.4 40 rpm: < 0.25 TRD-1926-01A 500 lb/in RC (FP) 6.56 - 5.99 40 rpm: 14.6 - 30.3 40 rpm: 0.5, 1 tablet capped at 20 Kn TRD-1926-01B 1,500 lb/in RC (FP) 6.5-5.84 40 rpm: 13.9- 32 40 rpm: 0.25 TRD-1771-33 Not RC 6.59-5.97 40 rpm: 18.3 - 27.2 40 rpm: 0.6, lamination at 20Kn Roller compaction improved bulk powder flow and compression profile without the use of pre-compression. The acceptable 5 hardness range was 10 to 13Kp and 11 to 25Kp for the lOOmg and 150mg tablets, respectively. Lamination was observed at compression forces greater than 18 KN for the 150mg tablet. The formulation does not appear to be dwell time sensitive. The lab phase FMI activities will start pending the confirmation of the 10 FMI tablet shape and size for the lOOmg strength. II. Analytical Investigations for Stress Tests of Variants A. Elaboration of Analytical Methods Assay and Related Substances The assay of vildagliptin and the quantitation of 15 degradation products of vildagliptin were performed by a gradient HPLC method [AM54001B(AS6105)]. The sample was extracted with methanol and diluted to target concentration using 10:90 methanol/acetonitrile and then chromatographed using a reverse phase HPLC method with UV detection at 210 nm. 20 Drug Release Dissolution of vildagliptin from six lOOmg vildagliptin tablets was determined under the test conditions elaborated in Table 3-1 WO 2006/135723 PCT/US2006/022416 -79- Samples obtained were analyzed by using an ■isocratic reverse phase HPLC method [AM50161A(AS6105)] with UV detection at 2010 nm. Same experimental have been done for the 150mg and 200mg tablets. 5 B. Analytical Results Stability Protocol The technical and clinical batches, slow and fast formulations of CSF were put on stability and the stability was monitored up to 12 months. The stability of technical batches of MF variants, 10 lOOmg and 150mg is currently ongoing as shown in the protocol, Table 3-2. Table 3-2 Drug product stability - storage conditions and testing intervals batch TRD-1926-078A(100mg), and TRD-1926-078B (150mg); [packaging: HDPE, CR cap, lg desiccant]. Storage condition Time (months) 5°C [24] 25°C/60%RH 3, 6, 9, 12, 24 30°C/65%RH [3], [6], [9], [12] 40°C/75%RH 1.5, 3, 6 [ ] Optional testing 15 Stability Results - 80 - Table 3-3 Summary of stability for vildagliptin 100 mg tablets, TRD-0739-0113 Degradation products %Unk, %Unk %Unk %Total % (RRT = - ■ deg. / 0 Moistur Conditions Tim Appearance %Assa % %Cycli %Diket 0.26) (RRT (RRT e e y Amide c = SS 0.77) 1.10) Initia 1 Complies 100.8 <LOQ <LOD ND ND <LOQ <LOQ - 3.52 25°C/60%RH 3M Complies 102.6 <LOQ <LOQ <LOQ ND <LOQ <LOQ - 2.40 6M Complies 101.0 0.06 0.05 <LOQ ND <LOQ <LOQ 0.11 2.66 9M Complies 100.1 0.08 0.05 <LOQ ND <LOQ <LOQ 0.13 2.74 12M Complies 102.5 0.11 0.05 <LOQ ND <LOQ <LOQ 0.16 3.16 30°C/60%RH 3M Complies 102.3 0.06 <LOQ <LOQ ND <LOQ <LOQ 0.06 2.51 6M Complies 104.3 0.12 0.05 <LOQ ND <LOQ <LOQ 0.17 2.79 9M Complies 100.3 0.17 0.05 <LOQ ND <LOQ <LOQ 0.22 3.07 12M Complies 100.7 0.21 0.05 0.07 ND <LOQ <LOQ 0.33 3.59 40°C/75%RH 6W Complies 101.4 0.10 0.05 <LOQ ND <LOQ <LOQ 0.15 2.73 3M Complies 103.3 0.20 0.05 0.07 ND <LOQ <LOQ 0.32 2.90 6M Complies 100.7 0.39 0.05 0.12 <LOQ <LOQ <LOQ 0.56 3.35 NT = not tested, Cyclic = cyclic amidine, Diketo = diketopiperazine, LOQ = 0.05% for cyclic, diketo and amide, 0.06% for vildagliptin; LOD = 0.02%; ND = Not Detected -81- Table 3-4 Summary of dissolution data for vildagliptin lOOmg tablets, TRD-0739-0113 Conditions Tim e 0.5 hr 1 hr 2 hr Percent released 4 hr 6 hr 8 hr 10 hr 12 hr 18 hr 24 hr Initia 1 23 36 56 82 95 102 104 104 104 102 25°C/60%RH 3M NT 6M NT 9M NT 12M NT 30°C/60%RH 3M NT 6M NT 9M NT 12M 24 57 94 100 40°C/75%RH 6W NT 3M 23 38 57 84 98 103 103 104 102 101 6M 24 - 57 95 - - 100 - NT = Not tested Note: Dissolution was tested only at accelerated conditions as these represent worst case situation. -82- Table 3-5 Summary of stability for vildagliptin lOOmg tablets, TRD-0739-0121 Degradation products Conditions Tim e Appearanc e %Assay % Amide %Cyclic %Diket. %Unk. (RRT= 0.26) %Unk. (RRT= 0.77) %Unk. (RRT= 1.10) %Total % Moisture Initia 1 complies 103.1 <LOQ <LOD ND ND <LOQ 0.07 0.07 3.19 25°C/60%RH 3M Complies 103.3 <LOQ <LOQ <LOQ ND <LOQ <LOQ 0.00 2.53 6M Complies 104.3 0.05 <LOQ <LOD ND <LOQ <LOQ 0.05 2.70 9M Complies 102.2 0.07 <LOQ <LOQ ND <LOQ <LOQ 0.07 3.03 12M Complies 101.4 0.08 <LOQ <LOQ ND <LOQ <LOQ 0.08 3.31 30°C/60%RH 3M Complies 104.7 0.05 <LOQ <LOQ ND <LOQ <LOQ 0.05 2.61 6M Complies 103.9 0.09 <LOQ <LOQ ND <LOQ <LOQ 0.09 2.88 9M Complies 100.8 0.11 <LOQ <LOQ ND <LOQ <LOQ 0.11 3.33 12M Complies 102.4 0.14 <LOQ 0.05 ND <LOQ <LOQ 0.19 3.65 40°C/75%RH 6W Complies 102.1 0.08 <LOQ <LOQ ND <LOQ <LOQ 0.08 2.81 3M Complies 104.8 0.13 <LOQ 0.05 ND <LOQ <LOQ 0.18 2.97 6M Complies 102.9 0.25 <LOQ 0.08 <LOQ <LOQ <LOQ 0.33 3.52 NT = not tested, Cyclic = cyclic amidine, Diketo = diketopiperazine, LOQ = 0.05% for cyclic, diketo and amide, 0.06% for vildagliptin; LOD = 0.02%; ND = Not Detected -83- Table 3-6 Summary of dissolution data for vildagliptin lOOmg tablets, TRD-0739-0121 Percent released Conditions Tim e 0.5 hr 1 hr 2 hr 4 hr 6 hr 8 hr 10 hr 12 hr 18 hr 24 hr Initial 12 20 30 45 56 65 72 78 89 95 25°C/60%RH 3M 6M 9M 12M NT NT NT NT 30°C/60%RH 3M 6M 9M 12M NT NT NT 13 32 60 94 40°C/75%RH 6W NT 3M 13 21 32 49 59 70 77 83 93 98 6M 13 33 - 61 - - - 95 - NT = Not tested Note: Dissolution was tested only at accelerated conditions as these represent worst case situation. -84- Table 3-7 References for the stability data in Table 3-3 through Table 3-6 Assay & Purity % Moisture Content Dissolution Initial TRD0958/057 (XG) TRD0958/109 (XG) WS18431 6W TRD0958/057 (XG) TRD0958/109 (XG) NA 5 3M TRD0983/082 (XG) TRD0978/110 (MZ) WS20247 6M TRD1514/110 (XG) TRD1514/110 (XG) WS21349 9M TRD1645/129 (MZ) TRD1645/101 (MZ) NA 12M TRD1642/069 (JT) TRD1642/145 (JT) WS22591 -85- Table 3-8 Summary of stability for vildagliptin lOOmg tablets, AEUS/2002-0080 Degradation products %Unk %Unk %Unk % a , a Tota % Conditions Tim Appearanc %Assa % %Cycli %Diket (RRT (RRT (RRT I Mois e e y Amide c = = as re 0.26) 0.77) 1.10) ueg. initial 0 complies 102.0 ND ND ND - - 2.62 5°C 3M complies 104.3 0.02 0.02 ND ND 0.04 0.03 0.00 2.17 6M complies 101.8 0.02 0.02 ND ND 0.05 0.03 0.00 2.32 9M complies 102.3 0.02 0.03 ND ND 0.04 ND 0.00 2.39 12M NT 25°C/60%RH 3M complies 101.1 0.04 0.05 ND ND 0.04 0.03 0.05 2.06 6M complies 103.0 0.07 0.06 0.02 ND 0.04 0.04 0.13 2.34 9M complies 100.6 0.08 0.06 0.02 ND 0.04 ND 0.14 2.43 12M complies 101.9 0.09 0.05 0.02 ND 0.03 0.02 0.14 2.72 25°C/60%RH 3M complies 101.4 0.04 0.05 ND ND 0.04 0.03 0.05 2.22 (With Cotton) 6M complies 102.0 0.06 0.06 ND ND 0.04 0.05 0.12 2.67 9M complies 102.2 0.09 0.07 ND ND 0.04 ND 0.16 2.69 12M complies 101.7 0.11 0.07 0.03 0.02 0.04 0.02 0.18 2.85 Degradation products °C/60%RH 3M complies 102.6 0.06 0.06 ND ND 0.04 0.04 0.12 2.12 6M complies 102.7 0.11 0.06 0.03 ND 0.04 0.05 0.17 2.60 9M complies 101.7 0.15 0.07 0.03 ND 0.03 ND 0.22 2.78 12M complies 101.3 0.19 0.06 0.05 ND 0.03 0.02 0.30 2.80 40°C/75%RH 6W complies 101.7 0.10 0.06 0.03 ND 0.04 0.06 0.22 2.28 3M complies 101.9 0.20 0.07 0.05 ND 0.03 0.05 0.32 2.59 6M complies 102.5 0.40 0.07 0.11 0.03 0.04 0.06 0.64 3.41 NT = not tested, Cyclic = cyclic amidine, Diketo = diketopiperazine, LOQ = 0.05% for cyclic, diketo and amide, 0.06% for vildagliptin; LOD = 0.02%; ND = Not detected -87- Table 3-9 Summary of dissolution data for vildagliptin lOOmg tablets, AEUS/2002-0080 Conditions Tim e 0.5 hr 1 hr 2 hr Percent released 4hr 6 hr 8 hr 10 hr 12 hr 18 hr 24 hr Initial 24 37 55 79 92 99. 101 101 100 99 25°C/60%RH 3M NT 6M NT 9M NT 12M NT 25°C/60%RH 3M NT (With cotton) 6M NT 9M NT 30°C/60%RH 3M NT 6M NT 9M 22 53 90 102 12M NT 40°C/75%RH 6W NT 3M 23 54 92 101 6M 24 56 93 104 NT = Not tested Note: Dissolution was tested only at accelerated conditions as these represent worst case situation. Table 3-10 Summary of stability data for vildagliptin lOOmg tablets, AEUS/2002-0081 Degradation products %Unk. %Unk. %Unk. % (RRT (RRT (RRT Total 0/ /o Conditions Time Appearance %Assay % Amide %Cyclic %Dike t = 0.26) = 0.77) = 1.10) deg. Moistur e Initial 0 complies 102.5 ND ND ND - - - 2.45 5°C 3M complies 103.4 0.02 0.01 ND ND 0.04 0.04 0.00 2.35 6M complies 102.7 0.02 0.02 ND ND 0.04 0.05 0.00 2.19 9M complies 101.4 0.02 ND ND ND 0.04 0.02 0.00 2.24 12M NT 25°C/60%RH 3M complies 103.1 0.03 0.03 ND ND 0.04 0.05 0.00 2.01 6M complies 102.9 0.05 0.03 ND ND 0.05 0.07 0.12 2.33 9M complies 100.8 0.06 0.03 ND ND 0.04 ND 0.06 2.44 12M complies 101.7 0.07 0.03 0.02 0.02 0.04 0.04 0.07 2.57 25°C/60%RH 3M complies 101.8 0.03 0.03 ND ND 0.04 0.04 0.00 2.14 (With Cotton) 6M complies 104.1 0.05 0.04 ND ND 0.04 0.06 0.11 2.61 9M complies 102.9 0.06 0.04 ND ND 0.04 ND 0.06 2.58 12M complies 104.9 0.08 0.03 0.02 ND 0.03 0.03 0.08 2.57 30°C/60%RH 3M complies 101.0 0.05 0.03 0.01 ND 0.04 0.05 0.05 2.06 6M complies 103.4 0.08 0.04 0.03 ND 0.04 0.07 0.15 2.64 9M complies 102.3 0.10 0.04 0.03 ND 0.03 ND 0.10 2.75 12M complies 101.0 0.13 0.04 0.04 0.02 0.04 0.03 0.13 2.62 40°C/75%RH 6W complies 102.8 0.07 0.03 0.03 ND 0.04 0.07 0.14 2.24 3M complies 102.6 0.13 0.04 0.03 ND 0.04 0.05 0.13 2.63 6M complies 103.1 0.25 0.05 0.08 0.02 0.04 0.07 0.45 3.58 NT = not tested, Cyclic = cyclic amidine, Diketo = diketopiperazine, LOQ = 0.05% for cyclic, diketo and amide, 0.06% for vildagliptin; LOD = 0.02%; ND = Not detected -89- Table 3-11 Summary of dissolution data for vildagliptin lOOmg tablets, AEUS/2002-0081,30HDPE90 Percent released Conditions Tim 0.5 hr 1 hr 2 hr 4hr 6 hr 8 hr 10 hr 12 hr 18 hr 24 hr e Initia 13 21 33 49 61 70 77 83 94 98 25°C/60%RH 3M NT 6M NT 9M NT 12M NT 25°C/60%RH 3M NT (With cotton) 6M NT 9M NT 30°C/60%RH 3M NT 6M NT 9M 13 33 62 95 12M NT 40°C/75%RH 6W NT 3M 12 31 57 89 6M 12 30 56 89 NT = Not tested Note: Dissolution was tested only at accelerated conditions as these represent worst case situation. Table 3-12 Summary of stability data for vildagliptin 200mg tablets, AEXJS/2002-0082 Degradation products %Unk %Unk %Unk n (RRT (RRT % Conditions Tim Appearanc %Assa % %Cycli %Diket (RRT 2 = %Total Mois e e y Amide c • 0.26) 0.77) 1.10) re Initial 0 complies 100.6 ND ND ND - - 2.61 5°C 3M complies 100.7 0.02 0.02 ND ND 0.04 0.02 0.00 2.23 6M complies 100.3 0.02 0.02 ND ND 0.04 0.03 0.00 2.54 9M complies 99.9 0.02 0.02 ND ND 0.04 ND 0.00 2.46 12M NT 25°C/60%RH 3M complies 100.6 0.04 0.04 ND ND 0.04 0.02 0.00 2.16 6M complies 100.1 0.06 0.05 ND ND 0.04 0.04 0.11 2.50 9M complies 99.9 0.08 0.06 0.02 ND 0.03 ND 0.14 2.56 12M complies 99.9 0.09 0.05 0.03 0.02 0.03 0.02 0.14 2^53 25°C/60%RH 3M complies 100.8 0.04 0.05 ND ND 0.04 0.02 0.05 2.22 (With Cotton) 6M complies 99.3 0.06 0.05 ND ND 0.04 0.04 0.11 2.59 9M complies 99.1 0.08 0.05 0.02 ND 0.03 ND 0.14 2.64 12M complies 100.3 0.10 0.06 0.03 0.02 0.03 0.02 0.16 2.63 30°C/60%RH 3M complies 99.5 0.06 0.06 ND ND 0.04 0.03 0.12 2.18 6M complies 100.8 0.11 0.05 0.03 ND 0.04 0.04 0.16 2.59 9M complies 100.4 0.16 0.06 0.03 ND 0.03 ND 0.22 2.75 12M complies 99.2 0.19 0.05 0.05 0.02 0.03 0.02 0.29 2.77 40°C/75%RH 6W complies 101.2 0.11 0.05 0.03 ND 0.03 0.06 0.22 2.31 3M complies 99.3 0.20 0.05 0.05 ND 0.03 0.03 0.30 2.51 6M complies 99.5 0.36 0.05 0.10 0.02 0.04 0.05 0.51 3.16 NT = not tested, Cyclic = cyclic amidine, Diketo = diketopiperazine, LOQ = 0.05% for cyclic, diketo and amide, 0.06% for vildagliptin; LOD = 0.02%; ND = Not detected -91- Table 3-13 Summary of dissolution data for 200mg tablets, AEUS/2002-0082 Percent released Conditions Tim e 0.5 hr 1 hr Initia [ 24 36 5°C I 3M NT 6M NT 9M NT 12M NT 25°C/60%RH 3M NT 6M NT 9M NT 12M NT 25°C/60%RH 3M NT (With cotton) 6M NT 9M NT 30°C/60%RH 3M NT 6M NT 9M 23 12M NT 40°C/75%RH 6W NT 3M 24 6M 25 52 73 86 93 98 99 99 97 51 84 99 52 87 99 54 87 99 NT = Not tested Note: Dissolution was tested only at accelerated conditions as these represent worst case situation. Table 3-14 Summary of dissolution data for 200mg tablets, AEUS/2002-0083 Degradation products %Unkn %Unkn %Unkn (RRT = (RRT = (RRT = 0/ /o Conditions Tim Appearanc %Assa % %Cycli %Diket 0.26) 0.77) 1.10) %Total Mois e e y Amide c re Initial 0 complies 100.8 ND ND ND - - 2.36 5°C 3M complies 100.8 0.02 ND ND ND 0.04 0.03 0.00 2.06 6M complies 100.5 ND ND ND ND 0.04 0.04 0.00 2.41 9M complies 101.1 ND ND ND ND 0.04 0.03 0.00 2.36 12M NT 25°C/60%RH 3M complies 99.9 0.03 0.02 ND ND 0.04 0.03 0.00 2.04 6M complies 100.6 0.05 0.03 ND ND 0.04 0.05 0.05 2.32 9M complies 99.6 0.06 0.03 ND ND 0.03 0.02 0.06 2.49 12M complies 100.2 0.08 0.02 0.02 0.02 0.04 0.04 0.08 2.50 25°C/60%RH 3M complies 100.5 0.03 0.03 ND ND 0.04 0.04 0.05 2.09 (With Cotton) 6M complies 100.2 0.05 0.03 ND ND 0.04 0.05 0.05 2.50 9M complies 100.1 0.07 0.03 ND ND 0.03 ND 0.07 2.66 12M complies 100.0 0.08 0.03 0.02 ND 0.04 0.03 0.08 2.54 30°C/60%RH 3M complies 100.4 0.05 0.03 ND ND 0.04 0.04 0.05 2.07 6M complies 100.3 0.08 0.03 0.02 ND 0.04 0.08 0.16 2.52 9M complies 100.2 0.11 0.03 0.03 ND 0.04 ND 0.11 2.67 12M complies 100.3 0.13 0.02 0.05 0.02 0.04 0.03 0.18 2.71 40°C/75%RH 6W complies 101.2 0.08 0.03 0.03 ND 0.03 0.08 0.16 2.24 3M complies 100.7 0.14 0.03 0.03 ND 0.03 0.04 0.14 2.47 6M complies 99.8 0.23 0.03 0.07 0.02 0.04 0.06 0.36 3.14 NT = not tested, Cyclic = cyclic amidine, Diketo = diketopiperazine, LOQ = 0.05% for cyclic, diketo and amide, 0.06% for vildagliptin; LOD = 0.02%; ND = Not detected -93- Table 3-15 Summary of dissolution data for 200mg tablets, AEUS/2002-0083 Conditions Tim e 0.5 hr 1 hr 2 hr Percent released 4 hr 6 hr 8 hr 10 hr 12 hr 18 hr 24 hr Initia I 11 18 27 40 50 59 66 71 84 91 5°C I 3M NT 6M NT 9M NT 12M NT 25°C/60%RH 3M NT 6M NT 9M NT 12M NT 25°C/60%RH 3M NT (With cotton) 6M NT 9M NT 30°C/60%RH 3M NT 6M NT 9M 11 27 51 84 12M 10 25 48 81 40°C/75%RH 6W NT - 3M 10 25 49 81 6M 10 25 48 81 NT = Not tested Note: Dissolution was tested only at accelerated conditions as these represent worst case situation. -94- Table 3-16 References for the stability data in Table 3-8 through Table 3-15 Reference Assay & Purity Moisture Content Dissolution Initial WS17548 TRD0958/109XG WS19437,19427,19449,1945 5 6W WS20721 TRD0983/99XG NA 3M WS20768 WS20768 WS21307, 20772, 21321 6M WS21855 WS21855 WS22761, 22771,22775 9M WS23831 WS23831 WS22591, 22599 12M WS25593 WS25593 WS25471, 25507 - 95 - Table 3-17 Summary of stability data for lOOmg tablets, TRD-1926-078A (packaging: HDPE, lg desiccant and CR cap) Degradation products %Unk. %Unk %Unk %Total % Moistur (RRT = - ■ deg. Conditions Tim Appearanc %Assa % %Cycli %Diket 0.26) (RRT (RRT e e e y Amide c 0.77) 1.10) Initia Complies 102.0 <LOQ <LOQ ND ND <LOQ <LOQ <LOQ 2.39 I 40°C/75%RH 6W Complies 98.3 0.10 0.06 <LOQ <LOQ <LOQ 0.06 0.22 NT = not tested, Cyclic = cyclic amidine, Diketo = diketopiperazine, LOQ = 0.05% for cyclic, diketo and amide, 0.06% for vildagliptin; LOD = 0.02%; ND = Not Detected. Ref: Initial -TRD 1928/127 JT: 6W-TRD 1980/ Table 3-18 Summary of dissolution data for lOOmg tablets, TRD-1926-078A (packaging: HDPE, lg desiccant and CR cap) Percent released Conditions Time 0.25 0.5hr 1 hr 2hr 4 hr 6 hr 8 hr 10 hr 12 hr 18 hr Jir Initial 7.6 12.3 19.5 30.5 46.5 - 68.4 82.3 89.1 93.8 40°C/75%RH 6W Not tested Ref: WS35331 KE -96- Table 3-19 Summary of stability data for 150mg tablets, TRD-1926-078B (packaging: HDPE, lg desiccant and CR cap) Degradation products Conditions Tim Appearanc %Assa % e e y Amide Initia Complies 101.7 <LOQ <LOQ ND ND <LOQ <LOQ <LOQ 2.31 I 40°C/75%RH 6W Complies 99.1 0.10 0.07 <LOQ ND <LOQ 0.06 0.23 NT = not tested, Cyclic = cyclic amidine, Diketo = diketopiperazine, LOQ = 0.05% for cyclic, diketo and amide, 0.06% for vildagliptin; LOD = 0.02%; ND = Not Detected Ref: Initial - TRD1928/127 JT: 6W - TRD Table 3-20 Summary of dissolution data for 150mg tablets, TRD-1926-078B(packaging: HDPE, lg desiccant and CR cap) Percent released Conditions Time 0.25h 0.5 hr 1 hr 2 hr 4hr 6 hr 8 hr 10 hr 12 hr 18 hr r Initial 6.8 11.1 17.7 28.3 - 43.9 65.1 79.5 86.5 91.5 40°C/75%RH 6W Not teste d %Unk. %Unk %Unk %Total % (RRT - deg. Moistur %Cycli %Diket 0.26) (RRT (RRT " c = = 0.77) 1.10) Ref: WS35331 KE -97- Table 3-21 Summary of assay and related substances data for the initial analysis of l-[(3-Hydroxy-adamant-l-ylamino)-acetyl]-pyrroIidine-2(S)-carbonitrile MR tablets (technical batches) Batch no. Appearanc %Assa % e y Amide Degradation products %Unk. (RRT = %Cycli %Diket 0.26) c %Unk %Unk %Total deg. % (RRT (RRT Moistur = = e 0.77) 1.10) TRD-1971- 053C 100mg Complies 100.9 ND ND ND ND <LOQ ND <LOQ 2.44 TRD-1971- 055A 150mg Complies 120.4 ND ND ND ND <LOQ ND <LOQ 2.31 NT = not tested, Cyclic = cyclic amidine, Diketo = diketopiperazine, LOQ = 0.05% for cyclic, diketo and amide, 0.06% for vildagliptin; LOD = 0.02%; ND = Not Detected Ref: TRD 1980/096 JT Table 3-22 Summary of dissolution data for the initial analysis of vildagliptin MR tablets (technical batches) Batch no. 0.25hr 0.5 hr Percent released 1 hr 2 hr 4 hr 6 hr 8 hr 10 hr 12 hr 18 hr TRD-1971-053C 100mg TRD-1971-055A 150mg Ref: WO 2006/135723 PCT/US2006/022416 -98- Specifications Tentative analytical specifications were laid down in specifications during early development of vildagliptin 25mg, 50mg and lOOmg tablets [AS6105B]. 5 III. Conclusions A Clinical Service Form (CSF) was developed to provide a "slow" release profile containing 40% HPMC K100M as the controlled release polymer. A direct compression powder blend was developed for the lOOmg and 150mg strengths. It was determined that the 10 use of roller compaction improved the compression profile and bulk powder flow of the CSF. Roller compaction exhibits a dissolution profile similar to the CSF (which was tested in vivo in humans) . The formulation does not appear to be effected by roller compaction roll speed, or dwell time on compression. 15 For the CSF lOOmg, 150mg and 200mg strengths, the stability data are available up to 12 months at 25°C/60%RH and 30°60%RH. The appearance, assay, purity and dissolution data were found to within specification limits after 12 months at 30°C/60%RH. These data support a 24 month re-test period with specification "do 20 not store above 25°C" for lOOmg, 150mg and 200mg modified release tablets. The composition of vildagliptin 150mg modified release tablets is bracketed by lOOmg and 200mg strengths. Therefore, the stability of 150mg tablets is expected to be same as lOOmg and 200mg strengths. Thus a re-test period similar to 25 that of 100 and 200mg strengths is applied for 150mg tablets. The stability profile of lOOmg and 150mg tablets manufactured by roller compaction after 6W, 40°C/75%RH was found to be comparable to that of CSF formulations. Thus, the stability does not appear to be affected by the inclusion of roller compaction 30 step in the manufacturing process. The roller compacted formulation containing 40% or 30% HPMC K100M has been selected. Preferred formulations are described in the below table: WO 2006/135723 PCT/US2006/022416 -99- 100 150 Component mg/ unit % mg/ unit % Vildagliptin 100 25.0 150 25.0 Microcrystalline cellulose, PH102 120 30.0 180 30.0 Lactose, anhydrous DT 16 4.0 24 4.0 Hydroxypropyl-methylcelluose K100M 160 40.0 240 40.0 Magnesium stearate 4 1.0 6 1.0 Total tablet weight (mg) 400 600 KN number 3768652 6001732 Tablet diameter, shape 11 mm, FFBE 17x6.7mm, ovaloid The invention has been described in an illustrative m.anner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation. 5 Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described. 10 Example A : Mechanical stress (particle size distribution) The material in the desired particle size range can be produced from any form of LAF237 e.g. amorphous form or crystal form, by mechanical stress. This stress can be mediated by impact, shear or compression. In most commercially available grinding 15 equipment a combination of these principles occurs. For LAF237 preferably a mechanical impact or jet mill is used. The most preferable mechanical impact mill can be equipped with different kind of beaters, screens, liners or with pin plates. For our process preferably an impact mill with plate beater and a slit 20 screen 5 * 2.5 cm is used. The impact speed should be variable between 20 and 100 m/s (as peripheral speed) to adapt to any WO 2006/135723 PCT/US2006/022416 -100- batch to batch variation. In our case a peripheral speed of the beater of about 40 - 50 m/s is used. Pharmacokinetic and Pharmacodynamic study: AUC area under the concentration time curve AUCo-t The area under the plasma concentration-time curve from time zero to the last quantifiable data point t [ng*hr/mL] AUCo-inf or The area under the plasma concentration-time curve from time zero to infinity AUC (o-oo) [ng*hr/mL] BAPK Bioanalytics and Pharmacokinetics section Cmax maximum plasma concentration CRF case report / record form CRO Clinical Research Organization CV Coefficient of variation ECG Electrocardiogram DPP-4 dipeptidyl peptidase 4; dipeptidyl peptidase IV FMI Final Market Image GLP-1 glucagon-like peptide 1 ICH International Council on Harmonization IRB Institutional Review Board LAF237 Vildagliptin LC-MS/MS Liquid chromatography-mass spectrometiy/mass spectrometry LOQ limit of quantitation o.d. once a day PD Pharmacodynamics PK Pharmacokinetics p.o per os / by mouth / orally QC Quality Control SOP Standard Operating Procedures SD standard deviation tmax time to reach Cmax t./2 elimination half-life Vd/f volume of distribution, corrected for the absolute bioavailability 5 Study synopsis and assessment schedule Title of study: A randomized, open-label, three period, cross-over study to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerabiiity, of two new LAF237 100mg and 150mg modified release formulations in patients with type 2 diabetes. Objectives: 10 Primary objective • To evaluate the pharmacokinetic profiles {single and multiple dose) after oral administration of two dosage strengths (100mg and 150mg) of a modified release formulation of LAF237 in patients with type 2 diabetes. • To evaluate the effect of a modified release formulation of LAF237 at two dosage 15 strengths (100mg and 150mg) (single and multiple dose) on DPP-IV activity. WO 2006/135723 PCT/US2006/022416 -101- • To evaluate the safety and tolerabiiity of the modified release formulations after oral administration for 7 days to patients with type 2 diabetes. Secondary objective(s) • To evaluate the effect of a modified release formulation of LAF237 at two dosage 5 strengths (100mg and 150mg) on the glucose profile after 7 days of treatment. • To compare the pharmacokinetic profiles of the modified release formulations of LAF237 at two dosage strengths when given with and without an ADA breakfast. Design: This study is a single center, randomized, open-label, three-period, crossover design study. A total of 27 patients with type 2 diabetes (both male and female) are 10 enrolled. Each subject participate in a 28 day screening period, three base-line periods, three 11-day treatment periods separated by two 7-day washout periods and a study completion evaluation. Subjects are randomized to the following 3 treatment sequence groups under William's design. Sequence Period 1 Period 2 Period 3 I A B C II B C A III C A B 15 • Treatment A: • Day 1: 100mg LAF237 MR OD, single dose • Days 3-10: 100mg LAF237 MR OD, for 8 days • Day 11-17: Wash out • Treatment B: 20 • Day 1: 150mg LAF237 MR OD, single dose • Days 3-10: 150mg LAF237 MR OD, for 8 days • Day 11-17: Wash out • Treatment C: • Day 1: 50mg LAF237 BID, two doses 25 • Days 3-10: 50mg LAF237 BID, for 8 days • Day 11-17: Wash out Patients receiving metformin therapy are required to stop taking metformin for at least 21 days prior to dosing on Day 1. On the evening of Day -1, patients who satisfy all inclusion/exclusion criteria at screening (Days -28 to -2) enter the study center for 30 verification of inclusion/exclusion criteria, baseline evaluations and subsequent WO 2006/135723 PCT/US2006/022416 -102- randomization to one of three sequences. Patients remain domiciled until the morning of Day 3 (48 h after the first dose of LAF237 is given). On Day 1 of each treatment period, patients receive the first dose of LAF237 following an over night fast of 10-12 hours. They continue to fast for 5 hours post-dose. Patients 5 are discharged from the site after the Day 3 morning dose of LAF237 with study drug medication, instructions on how to administer drug at home during the out-patient treatment days (Days 3 to 7) and a dosing diary. The modified release formulation of LAF237 (100mg and 150mg) are administered once daily before breakfast and the 50mg LAF237 is administered twice daily, once 10 before breakfast and once before dinner. A dosing diary is kept by the patients for all non-domiciled doses. Patients return to the site on the morning of Day 5 for pre-dose pharmacokinetic sample collection. They are admitted to the site at least 10 h prior to the Day 8 morning dose of LAF237 and remain domiciled until the morning of Day 12 (48 h after 15 the Day 10 dose is given). On Day 9, patients are served an ADA breakfast within 30 minutes of the morning dose of LAF237. Meal times on all domiciled days are strictly enforced. Breakfast are served within 30 minutes of the morning dose, except on days 1 and 10 when patients fast for 5 hours after dosing. Lunch, dinner and a snack are served 5, 10 and 12 hours post-dose, 2 0 respectively. Screening Periods One, Two, and Three Days -28 to -2 Day -1 Days 1-2 Days 3-8 Day 9 Day 10-11 Days 12-17 Patients receiving metformin required to stop therapy on Day -21 B/L 48 hr Sampling under fasted Day 3: Start of multiple dosing 24 hr Sampling, ADA Rrpakfast 48 hr Sampling under fasted w/o (Not required after Period 3) conditions served conditions PK profile Days 5 and 8: Pre-dose PK sampling PK profiling PK profiling DPP-IV profile Days 3-7: Out patient Day 8: Domiciled DPP-IV profiling DPP-IV profiling Glucose profiling WO 2006/135723 PCT/US2006/022416 -103- Number of subjects: 27 patients with type 2 diabetes (male and female) Criteria for inclusion: • Male and female (postmenopausal, surgically sterile or using double-barrier method of contraception) type two diabetic patients between 20 and 65 years of 5 age. • HblAc range between 6.5 and 9%. • Body mass index between 22 - 40 kg/m2. • Patients must be drug-naive to diabetic medications or on metformin treatment. • Patients must be able to complete a 3 week wash-out of current metformin therapy. 10 Patients will monitor FPG at home and call PI if values exceed 250mg/dL. • Patients must not be taking prescription or non-prescription medications. • Patients must have a fasting blood glucose of 7.0 - 12.2 mmol/dL (100-240 mg/dL) at screening and at predose on Day 1. • Patients on diuretics or cyclic hormone therapy must be on stable dose (at least 3 15 months prior to screening) and the maintenance dose may not be adjusted during the study. • All subjects must be able to provide written informed consent prior to participation the study, Criteria for exclusion: 20 • History of type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes e.g. Cushing's syndrome and acromegaly. • Use of thiazolindiones in the previous 3 months. • History of ketoacidosis. • Need for insulin within the previous 3 months. 25 • Significant concomitant diseases or complications of diabetes. • Fasting triglycerides >5.1 mmol/L (>450 mg/dL) within the past 4 weeks. • Treatment with systemic steroids. • Patients with any history of gastrointestinal surgery e.g. partial bowel resections, partial gastric resections, etc. 30 Investigational drug: LAF237 100mg MR (herein described preferred modified release MR formulation ) LAF237 150mg MR (herein described preferred modified release MR formulation) LAF237 50mg (as described in the US provisional patent application No. 60/604274) Duration of treatment: 46 days total study length, including washout periods. WO 2006/135723 PCT/US2006/022416 -104- Treatment A (LAF237 100mq MR OD): Single dose treatment on Day land 8 days of multiple dose treatment starting on Day 3. Treatment B (LAF237 150mq MR OD): Single dose treatment on Day 1 and 8 days of multiple dose treatment starting on Day 3. 5 Treatment C (50mq BID): BID dose treatment on Day 1 and 8 days of multiple dose treatment starting on Day 3. Two 7 day wash out periods between above treatments. Assessments and evaluations: 10 Background, demographic and administrative assessments • Inclusion/exclusion criteria; Relevant medical history/Current medical conditions: screening, review at baselines Demography: screening Physical examination: screening, baselines, end of study 15 • Hepatitis screen, HIV screen: screening Alcohol test, Drug screen, Urine cotinine: screening, baselines Pregnancy test: screening, baselines, end of study Drug administration record: each time study drug is administered Meal record: days 1, 2, 8, 9, 10 and 11. 20 • Study completion information: end of study Comments: as required Safety and tolerabiiity assessments • Vital signs and body measurements • Body height: screening 25 • Body weight: screening, baselines, end of study • Body temperature: screening, baselines, end of study • Blood pressure, pulse rate: screening*, baseline*, predose and 1,6, 12, and 24 h postdose on Days 1, 2, 8, 9, and 10; end of study (Note: measurements are supine, or supine and after 3 min standing if indicated by an *asterisk) 30 • EGG evaluation: screening, baselines, end of study • Hematology; Blood chemistry; Urinalysis: screening, baselines, end of study • Adverse events; Concomitant medications/Significant non-drug therapies: from time of first administration of study drug until end of study Pharmacokinetic assessments WO 2006/135723 PCT/US2006/022416 -105- • Blood collection (2 mL blood per sample, heparin tubes (plasma)): On Days 1, 9*. 10: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,10,12,14,16,24,36, and 48 hr post-dose On Days 5 and 8: predose. 5 *Samples collected to 24 hr postdose on Day 9. The Day 10 predose sample will also serve as the Day 9 24 hr sample • Analvtes, media and methods: LAF237 in plasma will be determined by LC-MS-MS with LOQ at 2ng/mL. • PK parameters: AUC0-t, AUC (0.oo), Cmax, tmax, and Cmax/AUC(o.t) will be evaluated 10 for each treatment period. Pharmacodynamic assessments DPP-IV activity will be measured on Days 1.. 9 and 10. • Blood collection (1 mL blood per sample, EDTA tubes (plasma)): On Days 1, 9* and 10: pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36 15 and 48 hr post-dose *Samples collected to 24 hr post-dose on Day 9. The Day 10 predose sample will also serve as the Day 9 24 hr sample. Glucose samples on Day 9. • Blood Collection (2 mL blood per sample, sodium fluoride tubes (plasma)) 20 Following morning dose- 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5 (pre-lunch meal), 5.5, 5.75, 6, 6.5, 7, 8, 9.75 (prior to evening dose and pre-dinner meal), 10.25, 10.75, 11, 11.25, 11.5, 12, 12.5, 13, 14, 16 and 24 hr post-dose. Statistical methods Sample Size: The sample size is determined based on a two one-sided t-test at 5% 25 significance level (Chen et. al. 1997) for PK parameters. When test-reference ratio is equal to 0.95, a sample size of 24 subjects allow at least 88% power to meet the bioequivalence criterion, i.e., to have the 90% CI for test-reference ratio of a bioavailability measure contained in the bioequivalence range of (0.8, 1.25) if intrasubject CV is not greater than 0.20, or 72% power if the intra-subject CV is equal 30 to 0.25. The intrasubject CV values used in the sample size determination are derived from a previous study of similar formulation (LAF237A2214) in healthy subjects in which the largest observed intrasubject CV is around 0.20 for Cmax. Statistical analysis: An analysis of variance (ANOVA) are performed on log-transformed AUC and Cmax data using the PROC MIXED SAS procedure. The WO 2006/135723 PCT/US2006/022416 -106- sources of variation included in the ANOVA model are sequence, subject (sequence), period, and treatment, with subject (sequence) as random effect. Using the ESTIMATE statement of the PROC MIXED SAS procedure, the contrast are constructed between the test and the reference treatments to obtain the p-value, the estimated mean 5 difference, an the 90% confidence interval (CI) for the log-scale test-reference difference. The anti-logs of the estimated mean difference and the 90% CI constitute the ratio of geometric means and the 90% CI for the true test-reference ratio. The outputs from the comparison are tabulated. For comparison of bioavailability between MR OD and IR BID, the test will be the MR 10 OD and the reference are IR BID. The LAF237 AUC and Cmax are compared between the two treatments within the ANOVA. The PD endpoints are analyzed using the same ANOVA model as described above. Drug administration On Days 1, 3, 5, 8, 9 and 10 study medication arre administered by the study center personnel 15 with 240 mL of water between 0700 and 0800, after at least a 10-hour fast. All subjects are dosed within a maximum of a 1-hour interval. Subjects must be instructed not to chew the medication, but to swallow it whole. The investigator has to check each subject's mouth to ensure that the medication was swallowed. Unless performing a study assessment, subjects have to rest quietly in the upright position for the next 4 hours. With the exception of Days 1 20 and 10 when the first meal is served 5 hours post-dose, an ADA breakfast is served within 30 minutes of dosing. During Treatment C, patients receive the evening dose of 50mg LAF237 30 minutes prior to dinner. General study conditions and restrictions 2 5 Definition of study phases Screening "Screening" is defined as assessments made for 2 to 28 days prior to initiation of the study (i.e. prior to the day of first dosing, Day 1) to determine eligibility for entry into this study. Potentially eligible subjects whose screening examinations show any disqualifying abnormality 3 0 may have the examination repeated ONCE if the investigator wishes to enroll the subject. Baseline If not yet domiciled, subjects should be admitted to the study site at least 10-hours prior to dosing in each treatment period. "Baseline" is defined as the period of a subject's continuous presence at the study facility to 30 minutes prior to the administration of the study drug (i.e. WO 2006/135723 PCT/US2006/022416 -107- Day -1). Baseline activities include safety assessments, as outlined in the Study synopsis and on the Assessment schedule. Treatment period(s) Each treatment period includes the predose activities (within 30 minutes prior to dosing), drug 5 administration, the postdose evaluations until 24-hours after dosing, and - if applicable - the washout period until predose of the following treatment period. End of study End of study evaluations will be performed on the last day of the last treatment period, prior to discharge from the study site. 10 Domiciling and physician coverage Patients are confined to the study center for at least 10 hours before administration of study drug on Day 1 until one hour after study drug is administered on Day 3. Patients return to the study center on the morning of day 5 for pre-dose blood collection. Patients are domiciled at least 10 hours before study drug is administered on Day 8 until 48 hours after the Day 10 15 morning dose of LAF23 7 is received. Presence of a physician on site is expected at a minimum for the first 2 hours after dosing during each period. A physician shall be available by pager at all other times throughout the study. Dietary, fluid and other restrictions 2 0 During recruitment, informed consent review, and baseline .period, the subjects is informed and reminded of the following restrictions: • No strenuous physical exercise (e.g., weight training, aerobics, football) for 7 days before dosing until after the end of study evaluation. • Diet should be free of read meat for at least 72 hours prior to the study entry until the end 25 of study. • No alcohol for 72 hours before dosing until after the end of study evaluation. • Intake of xanthine (e.g. caffeine) containing food or beverage must be discontinued 49 hours prior to dosing. Consumption of such food and beverage (i.e. coffee, tea, soda, chocolate) is not permitted at any time while the subjects are domiciled. If a deviation 3 0 occurs during the domiciled period, it must be noted on the Comments CRF page. On all domiciled days, except Days 1 and 10, patients receive the study drug 30 minutes prior to an ADA breakfast and an overnight fast of 10 hours. On Day 1 and 10, no breakfast is served. During Treatment C, patients also receive the evening dose of study drug 30 minutes prior to 3 5 dinner. The tested drug should be administered with 240 mL (8 fl oz) of water. No fluid intake WO 2006/135723 PCT/US2006/022416 -108- apart from the fluid given at the time of drug intake is allowed from 2 h before until 2 h after dosing. Otherwise, subjects should have a fluid intake of at least 200 mL eveiy 4 hours during waking hours in addition to fluid taken with meals and medication. During domiciled days, lunch and dinner are served at 5 hours and 10 hours post dose, 5 respectively, and a large snack is served at 12 hours post dose. Subjects follow a standard weight maintaining diet while domiciled on non-dosing days. No other food is consumed at any time during confinement. Subjects should consume the entire contents of the meal. Meals should be similar in caloric content and distribution for all subjects on the day of dosing. 10 When meal and blood draw times coincide, blood is drawn BEFORE the meal is provided. Intake of xanthine (e.g., caffeine) containing food or beverages must be discontinued 48 hours before dosing. Consumption of such foods and beverages (i.e., coffee, tea, and soda, chocolate) is not permitted at any time while the subjects are domiciled. If a deviation occurs during the domicile period, it must be noted on the Comments CRF page. 15 Background, demographic and administrative assessments Inclusion/exclusion criteria Subject selection is to be established by checking through all standard inclusion/exclusion criteria. A relevant record (e.g. checklist) must be stored with the source documentation at the study site. Violation of any entry criterion excludes a subject from enrollment into the study 2 0 unless granted specific clearance by the sponsor. Drug administration record Date and time of dose administration is recorded in the Dosage administration record section of the CRF and - if applicable - on the Blood collection CRF page for pharmacokinetics and pharmacodynamic evaluations. 2 5 Meal record The date and start time of meal consumption is recorded in the appropriate section of the CRF for all domiciled days. Study completion information Information on the date the subject last took drug, the subject's completion or discontinuation 30 of the study and the reason for discontinuation of the study is recorded on the Study completion CRF page. WO 2006/135723 PCT/US2006/022416 -109- Pharmacokinetic assessments Blood collection : All blood samples is taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein. LAF237: For each scheduled LAF237 sample, collect a 2 mL blood sample into a sodium or 5 lithium heparin tube at the times specified in the assessment schedule. Handling of blood samples Immediately after each tube of blood is drawn, it should be inverted gently several times to insure the mixing of tube contents (e.g., anticoagulant). Avoid prolonged sample contact with the rubber stopper. Place the tube upright in a test tube rack (e.g. surrounded by ice or at room 10 temperature) until centrifugation. Within 15 minutes, centrifuge the sample between 3 and 5°C for 15 minutes at approximately 2500 rpm. Transfer all available plasma to a polypropylene screw-cap tube and freeze at -70°C or below within 60 minutes of venipuncture. Analytical method (s) Analytes, media and methods: LAF237 in plasma by LC-MS-MS; LLOQ at 2 ng/mL. 15 Pharmacodynamic assessments: All blood samples are taken either by direct venipuncture or an indwelling cannula inserted in a forearm vein from each patient. Glucose: For each scheduled glucose sample, collect a 2 mL blood sample into a sodium flouride (grey top) tube at the times specified in the assessment schedule. The central laboratory to be used for analysis of plasma glucose samples has not been determined at this 2 0 point. Once determined, a protocol supplement do outline the sample handling and data transfer procedures. DPP-IV: DPP-IV measurements is conducted by Novartis Laboratory. For each scheduled sample collection for DPP-4 enzymatic analysis, collect a 1 ml blood sample into a tube containing potassium EDTA. Invert gently several times to mix the contents of the tube. Avoid 2 5 prolonged sample contact with the rubber stopper. Place the tube upright in rack surrounded by ice until centrifugation. Within 15 minutes after collection, centrifuge the sample between 3 and 5°C for 15 mins at approximately 2500 rpm. Transfer all available plasma to a polypropylene screw-cap micro tube and freeze at -70°C or below within 60 minutes of venipuncture 3 0 For labeling and shipment instructions, see Part B, Section 9. Data analysis Analysis of the data will be under the direction of Novartis personnel. WO 2006/135723 PCT/US2006/022416 -110- General statistical considerations Sample size determination The sample size is determined based on a two one-sided t-test at 5% significance level (Chen et. al. 1997 - Chen KW, Chow SC, Li G (1997). A note on sample size determination for 5 bioequivalence studies with higher-order crossover designs. J Parmarcokin, Biopharm. 25: 753-765.) for PK parameters. When test-reference ratio is equal to 0.95, a sample size of 24 subjects allows at least 88% power to meet the bioequivalence criterion, i.e., to have the 90% CI for test-reference ratio of a bioavailability measure contained in the bioequivalence range of (0.8, 1.25) if intrasubject CV is not greater than 0.20, or 72% power if the infra-subject CV is equal 10 to 0.25. The intrasubject CV values used in the sample size determination are derived from a previous study of similar formulation [LAF237A2214] in healthy subjects in which the largest observed intrasubject CV is around 0.17 for Cmax. Background, demographic and administrative data analysis Descriptive statistics are provided for background and demographic variables such as age, 15 weight, height, gender and race. Relevant medical history, current medical conditions, results of laboratory screens, drug tests and any other relevant information are listed. Safety and tolerabiiity data analysis All subjects who received at least one treatment are included in the safety and tolerabiiity 2 0 evaluation. Pharmacokinetic data analysis All completed subjects are included in the pharmacokinetic data analysis. Pharmacokinetic variables The following pharmacokinetic parameters are evaluated for each treatment period: AUCo-t, 2 5 AUC (o-m), Cmax, tmax, ty3, and Cmax/AUC(o-t). Biofluid concentrations are expressed in mass per volume units. All concentrations below the limit of quantitation or missing data are labeled as such in the concentration data listings. Concentrations below the limit of quantitation are treated as zero in summary statistics and for the calculation of pharmacokinetic parameters. 3 0 Descriptive statistics of pharmacokinetic parameters include mean, SD, and CV, min and max. When a geometric mean is presented it is stated as such. A range of values is presented for selected variables. Since tmax is generally evaluated by a nonparametric method, median values and ranges are given for this parameter. Pharmacokinetic parameters are determined based on non-compartmental method(s) using 35 WinNonlin Pro. WO 2006/135723 PCT/US2006/022416 -Ill- Statistical methods for pharmacokinetic analyses An analysis of variance (ANOVA) are performed on log-transformed AUC and Cmax data using the PROC MIXED SAS procedure. The sources of variation included in the ANOVA model are sequence, subject (sequence), period, and treatment, with subject (sequence) as 5 random effect. Using the ESTIMATE statement of the PROC MIXED SAS procedure, the contrast are constructed between the test and the reference treatments to obtain the p-value, the estimated mean difference, an the 90% confidence interval (CI) for the log-scale test-reference difference. The anti-logs of the estimated mean difference and the 90% CI constitute the ratio of geometric means and the 90% CI for the true test-reference ratio. The outputs from the 10 comparison are tabulated. For comparison of bioavailability between MR OD and IR BID, the test treatment is the MR OD and the reference is IR BID. The LAF237 AUC and Cmax are compared between the two treatments within the ANOVA. Pharmacodynamic data analysis 15 All subjects who complete the trial with evaluable pharmacodynamic (PD) measurements are included in the data analysis. Pharmacodynamic variables Following glucose parameters may be derived for treatment comparison: AUE area under the effect-time curve from time 0 to last available observation by 2 0 the linear-trapezoidal rule Emax maximal effect (minimum value) troax time to the first occurrence of the maximal effect. In order not to lose data from subjects due to missing values, the algorithm below are employed to replace missing values: 25 • If the first or the last observation of a subject's record is missing then they are replaced by the second or the previous observation. • If an observation is missing within a series of non-missing observations, then the missing values are substituted by the result of a linear regression based on its neighbors. • If two consecutive observations are missing, then the record is completely ignored. 30 Statistical methods for pharmacodynamic analyses The glucose parameters are analyzed using the same ANOVA model as described above for statistical analysis of PK parameters. In addition, timepoint-wise comparison of glucose concentration are performed using the same ANOVA model as described above. 35 Results: WO 2006/135723 PCT/US2006/022416 -112- Pharmacokinetic results (described on figures 24, 25, 26) Treatment Tmax (h) median (min, max) Cmax (ng/mL) mean ± SD (CV%) AUC a (h*ng/mL) mean ± SD (CV%) CL/F (L/h) mean ± SD (CV%) tH (h) mean ± SD (CV%) Day 1 (Single Dose Fasted) (N=27) LAF237 100 mg MR OD 4.00 (1.50, 6.00) 205 ± 47 (23) 1449 ± 376 (26) 73.60 ± 19. 60 (27) 11.69 ± 5.68 (49) LAF237 150 mg MR OD 4.00 (1.50, 6.00) 257 + 59 (23) 2271 ± 925 (41) 75.63 + 28.54 (38) 10.75 ± 5.01 (47) LAF237 50 mg MR BID 1.00 (0.50, 4.00) 278 + 75 (27) 2159 ± 425 (20) 45.14 + 7.91 (18) 2.43 + 1.12 (46) Day 9 (Multiple Dose Fed) (N=27) LAF237 100 mg MR OD 2.00 (1.00, 6.00) 200 + 64 (32) 1489 + 488 (33) 75.45 + 29.07 (39) 8.70 + 3.75 (43) LAF237 150 mg MR OD 2.50 (1.00, 6.00) 272 ± 111 (41) 2242 + 965 (43) 78.84 + 31.30 (40) 10.34 ± 5.06 (49) LAF237 50 mg BID 1.00 (1.00, 4 . 00) 285 ± 91 (32) 1992 + 461 (23) 50.92 + 16.51 (32) 2.83 + 0. 62 (22) Day 10 (Multiple Dose Fasted) (N=27) LAF237 100 mg MR OD 3.00 (1.00, 6.00) 215 + 68 (31) 1638 ± 535 (33) 66.77 + 20.87 (31) 11.80 ± 5. 69 (48) LAF237 150 mg MR OD 4.00 (2.50, 6.00) 309 ± 91 (29) 2458 + 815 (33) 67.19 ± 21.27 (32) 10.54 ± 5.39 (51) LAF237 50 mg MR BID 2.00 (0.50, 9.97) 257 ± 60 (23) 2198 ± 492 (22) 44.92 ± 10.97 (24) 3.38 ± 2. 62 (77) a: AUCO-inf on Day 1, AUCO-24 on Days 9 and 10, AUCO-24 on Day 1 for LAF237 50 mg BID Results: 5 Pharmacodynamic results (described on figures 21, 22, 23) Treatment DPP-4-AUC24 (%.h) mean ± SD (CV% DPP-4-MRT (h) mean ± SD (CV%) DPP-4-Avg (%) mean ± SD (CV%) DPP-4-24h (%) mean ± SD (CV%) Day 1 (Single Dose Fasted) (N=27) LAF237 100 mg MR 2208 ± 73 (3) 11.8 ± 0.3 (3) 92.01 ± 3.03 85.64 ± 12.76 WO 2006/135723 PCT/US2006/022416 -113- OD (3) (15) LAF237 150 mg MR OD 2242 ± 70 (3) 11.9 ± 0.3 (3) 93.43 ± 2.93 (3) 90.04 ± 11.91 (13) LAF237 50 mg MR BID 2225 + 48 (2) 11.7 ± 0.2 (2) 92.69 ± 2.01 (2) 80.92 ± 9.03 (11) Day 9 (Multiple Dose Fed) (N=27) LAF237 100 mg MR OD 2240 ± 98 (4) 11.8 + 0.5 (4) 93.35 + 4.09 (4) 87.78 + 16. 37 (19) LAF237 150 mg MR OD 2270 ± 86 (4) 11.8 + 0.5 (4) 94.59 + 3.57 (4) 90.40 + 17.50 (19) LAF237 50 mg BID 2252 ± 33 (1) 11.8 ± 0.1 (1) 93.85 + 1.36 (1) 86.15 ± 4.78 (6) Day 10 (Multiple Dose Fasted) (N=27) LAF237 100 mg MR OD 2261 ± 40 (2) 11.9 ± 0.2 (1) 94.21 + 1.66 (2) 90.20 ± 7.35 (8) LAF237 150 mg MR OD 2281 ± 49 (2) 11.9 ± 0.2 (2) 95.06 ± 2.03 (2) 91.64 ± 8.47 (9) LAF237 50 mg MR BID 2243 ± 46 (2) 11.7 ± 0.2 (1) 93.44 + 1.94 (2) 82.80 + 7.39 (9) - 114 - RECIEVED IPONZ 29 NOVEMBER 2011 </div>

Claims

Claims:

1. A pharmaceutical tablet formulation comprising per unit dosage form the following ingredients: (a) a compound as an active ingredient, wherein the compound is (s)-1-[(3-hydroxy-l-adamantyl)amino]acetyl-2-cyano-pyrrolidine (vildagliptin) or the corresponding amount of any of its salts; and (b) hydroxypropyl methylcellulose K100M; and one or more fillers and optionally a lubricant.

2. The pharmaceutical tablet formulation according to claim 1, wherein in the unit dosage form, the ratio of the weight of vildagliptin and any of its corresponding salts to the weight of hydroxypropyl methylcellulose is of 0.16 to 2.5.

3. The pharmaceutical tablet formulation according to claim 2, wherein the ratio is 0.3 to 1.16 or 0.4 to 1.

4. The pharmaceutical tablet formulation according to any one of claims 1 to 3 comprising: (a) 15-55% by weight on a dry weight basis of the pharmaceutically acceptable filler(s), and optionally; (b) 0.1-10% by weight on a dry weight basis of the pharmaceutically acceptable lubricant.

5. The pharmaceutical tablet formulation according to claim 4, comprising: 24-45% by weight on a dry weight basis of a pharmaceutically acceptable filler(s).

6. The pharmaceutical tablet formulation according to claim 4 or claim 5, comprising: 0.1-3% by weight on a dry weight basis of a pharmaceutically acceptable lubricant.

7. The pharmaceutical tablet formulation according to any one of claims 1 to 6, wherein the filler is lactose and/or - 115 - RECIEVED IPONZ 29 NOVEMBER 2011 microcrystalline cellulose and the lubricant is magnesium stearate.

8. The pharmaceutical tablet formulation according to claim 7, wherein the lactose is present in an amount from 1% to 8% by weight.

9. The pharmaceutical tablet formulation according to any one of the preceding claims, wherein the compound is a crystal form of vildagliptin or any of its salts.

10. The pharmaceutical tablet formulation according to claim 9, wherein the crystal form is crystal form "A".

11. The pharmaceutical tablet formulation according to any one of claims 7 to 10, wherein relative to the weight of the formulation: (a) vildagliptin, or the corresponding amount of any of its salts is present in an amount from 15% to 35% by weight; (b) the hydroxypropyl methylcellulose is present in an amount from 3 0% to 50% by weight; (c) the microcrystalline cellulose is present in an amount from 25% to 35% by weight; and (d) the magnesium stearate is present in an amount from 0.1% to 3% by weight.

12. A pharmaceutical tablet formulation, comprising per 600 mg tablet the following ingredients: (a) vildagliptin in an amount of 150 mg, or the corresponding amount of any salt thereof; (b) hydroxypropyl methylcellulose K100M in an amount of about 2 4 0 mg; (c) a microcrystalline cellulose in an amount of 180 mg; (d) a lactose in an amount of about 24 mg; and (e) a magnesium stearate in an amount of 6 mg. - 116 - RECIEVED IPONZ 29 NOVEMBER 2011

13. A pharmaceutical tablet formulation, comprising per 400 mg tablet the following ingredients: (a) vildagliptin in an amount of 100 mg, or the corresponding amount of any salt thereof; (b) hydroxypropyl methylcellulose K100M in an amount of about 160 mg; (c) a microcrystalline cellulose in an amount of 120 mg; (d) a lactose in an amount of about 16 mg; and (e) a magnesium stearate in an amount of 4 mg.

14. A method of producing the pharmaceutical tablet formulation according to any one of claims 1 to 13, where the method comprises combining the ingredients in the amounts recited in any one of these claims.

15. A pharmaceutical multilayer tablet wherein the pharmaceutical tablet formulation according to any one of claims 1 to 13, represents one of the layers of the tablet.

16. The pharmaceutical multilayer tablet according to claim 15, wherein the further layer includes a glitazone, which may include pioglitazone or rosiglitazon, or metformin.

17. The pharmaceutical multilayer tablet according to claim 16 wherein the further layer is an immediate release formulation.

18. A pharmaceutical tablet obtained by compression of the pharmaceutical tablet formulation according to any one of claims 1 to 13.

19. A pharmaceutical tablet obtained by compression of the pharmaceutical tablet formulation according to any one of claims 1 to 13, wherein the pharmaceutical tablet formulation is subject to roller compaction before compression into tablet.

20. The pharmaceutical tablet according to claim 19 comprising 100 mg of vildagliptin or a pharmaceutically acceptable salt - 117 - RECIEVED IPONZ 29 NOVEMBER 2011 thereof wherein the tablet hardness range is of between 10 to 13 Kp.

21. The pharmaceutical tablet according to claim 19 comprising 150 mg of vildagliptin or a pharmaceutically acceptable salt thereof wherein the tablet hardness range is of between 11 to 2 5 Kp.

22. The pharmaceutical tablet formulation according to any one of claims 1 to 13 or the pharmaceutical tablet according to any one of claims 15 to 21, comprising at least one further therapeutic agent.

23. The pharmaceutical tablet formulation or the pharmaceutical tablet according to claim 22, wherein the at least one further therapeutic agent is an antidiabetic.

24. The pharmaceutical tablet formulation or the pharmaceutical tablet according to claim 23, wherein the antidiabetic agent is selected from pioglitazone, rosiglitazone and metformin.

25. The pharmaceutical tablet formulation or the pharmaceutical tablet according to claim 22, wherein the at least one further therapeutic agent is an angiotensin II antagonist or a statin.

26. A process for preparing a tablet, in unit dosage form, the process comprising the steps of: (a) blending a pharmaceutical tablet formulation according to any one of the preceding claims; (b) compressing the formulation prepared during step (a) to form the compressed tablet in unit dose form.

27. A process for preparing a tablet, in unit dosage form, the process comprising the steps of: (a) blending the pharmaceutical tablet formulation according to any one of claims 1 to 13 or 22 to 25; (b) roller compacting the formulation prepared during step (a); and - 118 - RECIEVED IPONZ 29 NOVEMBER 2011 (c) compressing the formulation prepared during step (b) to form the compressed tablet in unit dosage form.

28. A process for preparing a tablet, in unit dosage form, the process comprising the steps of: (a) blending the pharmaceutical tablet formulation according to any one of claims 1 to 13 or 22 to 25; (b) roller compacting the formulation prepared during step (a) with a compaction force comprised between 10 and 16 KN and; (c) compressing the formulation prepared during step (b) to form the compressed tablet in unit dosage form.

29. A sustained release solid oral pharmaceutical dosage form which is a dosage form according to any one of claims 1 to 10, and which is; i-1) a solid oral pharmaceutical dosage form comprising about 100 mg of vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 15.8 ng/mL +/- 6.85 ng/mL to about 173 ng/mL +/- 52 ng/mL between about 0.5 and about 16 hours following oral administration of said dosage form in a patient not treated with vildagliptin before said administration and wherein patient is under fasted conditions, and/or i-2) a solid oral pharmaceutical dosage form comprising about 100 mg of vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 26.3 ng/mL +/- 13.1 ng/mL to about 175 ng/mL +/- 62.5 ng/mL between about 0.5 and about 16 hours following administration of said dosage form on day 9 in a patient treated with said dosage - 119 - RECIEVED IPONZ 29 NOVEMBER 2011 form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or i-3) a solid oral pharmaceutical dosage form comprising about 100 mg of vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 26.9 ng/mL +/- 14.1 ng/mL to about 186 ng/mL +/- 80.6 ng/mL between about 0.5 and about 16 hours following administration of said dosage form on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, and/or ii-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC(0_lnf) of vildagliptin ranging from about 1073 to about 1825 ng*h/mL following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or ii-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC(0_24) of vildagliptin ranging from about 1001 to about 1977 ng*h/mL following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or - 120 - RECIEVED IPONZ 29 NOVEMBER 2011 ii-3) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC(0-24) of vildagliptin ranging from about 1103 to about 2173 ng*h/mL following oral administration of said dosage form, on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, and/or iii-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 3.61 hr +/- 1.44 hr following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or iii-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 2.59 hr +/- 1.4 hr following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or iii-3) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 3.74 hr +/- 1.44 hr following oral administration of said dosage form, on day 10 in a patient - 121 - RECIEVED IPONZ 29 NOVEMBER 2011 treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, and/or iv-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 205 ng/ml +/- 47 ng/ml following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or iv-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 200 ng/ml +/- 64 ng/ml following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or iv-3) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 245 ng/ml +/- 68 ng/ml following oral administration of said dosage form, on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, and/or v-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean % inhibition of DPP-IV activity over 24 hours of 85.64% +/- 12.7 6% following - 122 - RECIEVED IPONZ 29 NOVEMBER 2011 oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or v-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean % inhibition of DPP-IV activity over 24 hours of 87.78% +/- 16.37% following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or v-3) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean % inhibition of DPP-IV activity over 24 hours of 90.20% +/-7.35% following oral administration of said dosage form, on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, and/or vi-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as substantially depicted in figure 24, following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or vi-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile - 123 - RECIEVED IPONZ 29 NOVEMBER 2011 as substantially depicted in figure 25, following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or vi-3) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as substantially depicted in figure 26, following oral administration of said dosage form, on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions.

30. The sustained release solid oral pharmaceutical dosage form of claim 29, wherein for (ii-1) , the mean is 1449 ng*h/mL +/- 376 ng*h/mL.

31. The sustained release solid oral pharmaceutical dosage form of claim 29 or claim 30, wherein for (ii-2), the mean is 1489 ng*h/mL +/- 488 ng*h/mL.

32. The sustained release solid oral pharmaceutical dosage form of any one of claims 29 to 31, wherein for (ii-3), the mean is 1638 ng*h/mL +/- 535 ng*h/mL.

33. A sustained release solid oral pharmaceutical dosage form which is a dosage form according to any one of claims 1 to 10, and which is; i-a) a solid oral pharmaceutical dosage form comprising about 150 mg of vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 30.7 ng/mL +/- 21.9 ng/mL to about 223 ng/mL +/- 77.3 ng/mL between about 0.5 and about 16 hours following oral administration of - 124 - RECIEVED IPONZ 29 NOVEMBER 2011 said dosage form in a patient not treated with vildagliptin before said administration and wherein patient is under fasted conditions, and/or i-b) a solid oral pharmaceutical dosage form comprising about 150 mg of vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 48.7 ng/mL +/- 25.8 ng/mL to about 223 ng/mL +/- 99.7 ng/mL between about 0.5 and about 16 hours following administration of said dosage form on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or i-c) a solid oral pharmaceutical dosage form comprising about 150 mg of vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of vildagliptin ranging from about 44.6 ng/mL +/- 28.5 ng/mL to about 263 ng/mL +/- 84.4 ng/mL between about 0.5 and about 16 hours following administration of said dosage form on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, and/or ii-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC(0-inf) of vildagliptin ranging from about 1346 to about 3196 ng*h/mL following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or - 125 - RECIEVED IPONZ 29 NOVEMBER 2011 ii-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC(0-24) of vildagliptin ranging from about 1277 to about 3207 ng*h/mL following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or ii-c) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC(0-24) of vildagliptin ranging from about 1643 to about 3273 ng*h/mL following oral administration of said dosage form, on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, and/or iii-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 3.57 hr +/- 1.17 hr following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or iii-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 2.87 hr +/- 1.59 hr following oral administration of said dosage form, on day 9 in a patient - 126 - RECIEVED IPONZ 29 NOVEMBER 2011 treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or iii-c) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 4.13 hr +/- 1.24 hr following oral administration of said dosage form, on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, and/or iv-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 257 ng/ml +/- 59 ng/ml following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or iv-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 272 ng/ml +/- 111 ng/ml following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or iv-c) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier - 127 - RECIEVED IPONZ 29 NOVEMBER 2011 medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 308 ng/ml +/- 91 ng/ml following oral administration of said dosage form, on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, and/or v-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean % inhibition of DPP-IV activity over 24 hours of 90.04% +/- 11.91% following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or v-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean % inhibition of DPP-IV activity over 24 hours of 90.4% +/- 17.50% following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or v-c) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean % inhibition of DPP-IV activity over 24 hours of 91.64% +/-8.47% following oral administration of said dosage form, on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions, and/or vi-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a - 128 - RECIEVED IPONZ 29 NOVEMBER 2011 pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as substantially depicted in figure 24, following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or vi-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as substantially depicted in figure 25, following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form, and/or vi-c) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing a pharmacokinetic profile as substantially depicted in figure 26, following oral administration of said dosage form, on day 10 in a patient treated with said dosage form once a day since day 1 and wherein said patient is under fasted conditions.

34. The sustained release solid oral pharmaceutical dosage form of claim 33, wherein for (ii-a), the mean is 2271 ng*h/mL +/- 925 ng*h/mL.

35. The sustained release solid oral pharmaceutical dosage form of claim 33 or claim 34, wherein for (ii-b), the mean is 2242 ng*h/mL +/- 965 ng*h/mL.

36. The sustained release solid oral pharmaceutical dosage form of any one of claims 33 to 35, wherein for (ii-c) , the mean is 2458 ng*h/mL +/- 815 ng*h/mL. - 129 - RECIEVED IPONZ 29 NOVEMBER 2011

37. A sustained release solid oral pharmaceutical dosage form according to any one of claims 2 9 to 36, which comprises the pharmaceutical tablet formulation according to any one of claims 1 to 13 or 22 to 25.

38. A sustained release solid oral pharmaceutical dosage form according to any one of claims 29 to 37, which comprises a hydroxypropyl methylcellulose.

39. The sustained release solid oral pharmaceutical dosage form according to claim 38, which comprises between 20% and 60% by weight on a dry weight basis of a hydroxypropyl methylcellulose.

40. The sustained release solid oral pharmaceutical dosage form according to claim 38, which comprises between 30% and 50% by weight on a dry weight basis of a hydroxypropyl methylcellulose.

41. A sustained release solid oral pharmaceutical dosage form according to any one of claims 29 to 40, which comprises hydroxypropyl methylcellulose K100M.

42. A sustained release solid oral pharmaceutical dosage form according to any one of claims 29 to 41, wherein; i) the formulation is a matrix formulation containing a pharmaceutically acceptable hydrophilic polymer which can retard diffusion of vildagliptin, ii) the solid oral pharmaceutical dosage form is a compressed tablet, and optionally iii) the elution rate of vildagliptin at 30 minutes after starting the test is less than 30% when conducting the Paddle method.

43. Use of ingredients in amounts recited in any one of claims 1 to 42, in the manufacture of a pharmaceutical tablet formulation, for treating or ameliorating a condition, wherein said condition is selected from: non-insulin-dependent - 130 - RECIEVED IPONZ 29 NOVEMBER 2011 diabetes mellitus, arthritis, obesity, allograft transplantation, calcitonin-osteoporosis, heart failure, impaired glucose metabolism, impaired glucose tolerance, neurodegenerative disorders, cognitive disorders, cardiovascular diseases, renal diseases, hyperlipidemia, symptoms associated with hyperlipidemia, abnormal VLDL, LDL or Lp(a) levels, conditions requiring a sedative or anxiolytic effect, or in the manufacture of a tablet formulation for attenuating post-surgical catabolic changes, or hormonal responses to stress, or for reducing mortality or morbidity after myocardial infarction.

44. Use according to claim 43, wherein the condition is non insulin-dependent diabetes mellitus.

45. Use according to claim 43, wherein the condition is obesity, arthritis or osteoporosis.

46. Use according to any one of claims 43 to 45, wherein the pharmaceutical tablet formulation is formulated for combination with a therapeutically effective dose of an antidiabetic, arthritis drug or anti-obesity drug.

47. The pharmaceutical tablet formation of any one of claims 1 to 13 or 22 to 25 substantially as described herein with reference to any one of the Examples or Figures thereof.

48. The method of claim 14 substantially as described herein with reference to any one of the Examples or Figures thereof.

49. The pharmaceutical tablet of any one of claims 15 to 25 substantially as described herein with reference to any one of the Examples or Figures thereof.

50. The process of any one of claims 26 to 28 substantially as described herein with reference to any one of the Examples or Figures thereof. - 131 - RECIEVED IPONZ 29 NOVEMBER 2011

51. The sustained release solid oral pharmaceutical dosage form of any one of claims 29 to 42 substantially as described herein with reference to any one of the Examples or Figures thereof.

52. The use of any one of claims 43 to 46 substantially as described herein with reference to any one of the Examples or Figures thereof.